Patent Application
20240391948
The present invention relates to a novel compound for inhibiting TNF-α production and activation of inflammatory complexes that can be used for the treatment of various inflammatory diseases and a producing method therefor, and relates to a novel compound prepared by reacting bile acid or a derivative thereof with a taurine derivative.
The causes of inflammation are known to be PAMPs (Pathogen-associated molecular patterns) derived from pathogens and DAMPs (Damage-associated molecular patterns) released from tissues owing to the tissue damages. Immune cells activated due to these molecular patterns and other inflammatory mediators produced by cells such as blood vessels respond to a biological protection, but if this response is not properly balanced, it causes inflammatory diseases.
Intractable inflammatory diseases have a high recurrence rate and require a long-term administration of their treatment measures. However, all the treatment measures developed to date does not meet the market demand, and therefore, the development of new treatment measures is necessary. So far, steroids, NSAIDs (non-steroidal anti-inflammatory drugs), antibody treatments, and JAK inhibitors are being prescribed for the treatment of inflammatory diseases. However, steroid drugs are only prescribed for a short period of time due to its systemic side effects, and NSAIDs are not showing sufficient efficacy in clinical trials. In addition, antibody treatments have relatively fast responses and can be administered for a long period of time, but this measures has the disadvantage of having side effects at the injection site, a gradual decrease in efficacy due to the production of neutralizing antibodies in the body, and high-cost burden for the patient. JAK inhibitors have excellent anti-inflammatory effects, but they have a risk of increasing severe infections by excessively suppressing T lymphocytes, and cardiovascular side effects and carcinogenic risks have been confirmed.
To overcome the unmet market demand, agents regulating inflammatory complexes are recently drawing the attentions for the treatment measures. Inflammatory complexes, which are the core of the body's immune response, play an important function in innate defense immunity as part of the immune response to microbial infections and cell damages. Inflammatory complexes are cytosolic multiprotein oligomers of the innate immune system. Among many inflammatory complexes, abnormal activation of the NLRP3 inflammasome is associated with the onset and worsening of various inflammatory diseases such as ulcerative colitis, gout, multiple sclerosis, arthritis, sepsis, and inflammatory neurological disease. The NLRP3 inflammasome is also activated by PAMPs from pathogens such as viruses and bacteria, and DAMP stimuli such as calcium influx, mitochondrial reactive oxygen species, and extracellular APT. Activation of the inflammatory complex not only activates gasdermin-D through caspase-1, but also promotes protein maturation and secretion of pro-IL-1β and pro-IL-18 into IL-1β and IL-18. Disorders in the regulation of inflammatory complex activation cause various diseases such as cancer, metabolic diseases, degenerative diseases, and inflammatory diseases.
Attempts to develop new drugs targeting the NLRP3 inflammatory complex, a major regulator of inflammatory response, used to be taken several times in the past. As it became to be known that the inflammatory complex is activated through canonical and non-canonical pathways consisting of pro-caspase, gasdermin D, ASC, NLR protein, AIM2, IF116, and pyrin, and various diseases occur when dysregulation of the inflammatory complex occurs, the development of drugs targeting proteins involved in inflammatory complex-related signaling has become active since 2010. P2X7 receptor antagonist, NLRP3 inhibitor, and caspase-1 inhibitor are the representatives of developed inflammatory complex regulators.
Among these, one of the important receptors for activation of the NLRP3 inflammatory complex is P2X7R. The P2X7 receptor is an ion channel receptor composed of a complex belonging to the P2Xn purine receptor group. When P2X7 is stimulated, it promotes the extracellular release of potassium ions and the rapid movement of calcium and sodium ions into the cells. High concentrations of ATP released from necrotic cells act as pro-inflammatory DAMPs, binding to the P2X7 receptor and activating the NLRP3 inflammatory complex. Ultimately, it causes the release of potassium ions through the P2X7 receptor and the imbalance of intracellular ions in cells, which activaties the NLRP3 inflammatory complex. As such, the P2X7 receptor, which plays an important role in activating inflammatory complexes, is widely expressed on various immune cells, epidermal cells, or nerve cells, and since the P2X7 receptor signaling activates both canonical and non-canonical pathways of NLRP3 activation, the interaction of ATP-P2X7 is very important in NLRP3 inflammasome activation.
P2X7 antagonists were developed by global pharmaceutical companies such as Pfizer, AstraZeneca, and Janssen for indications such as rheumatoid arthritis, Crohn's disease, and depression, but most of them were discontinued due to the lack of efficacy in clinical trials. Afterwards, venture companies continued the development, but as of 2020, there are only less than 10 therapeutic development pipelines targeting P2X7, Janssen 18F-JNJ-64413739 being developed for depression treatment is in the completion stage of the 1st clinical trials, and other pipelines remain in the preclinical or development stage. Caspase-1 inhibitor has no global development pipeline as it was discontinued in 2020 due to the lack of efficacy targets and safety issues in clinical trials. NLRP3 inhibitor is being developed by venture companies such as OLATEC, IMFLAZOME, IFM THERAPETICS, NODTHERA, and AC Immune for indications such as osteoarthritis, systolic heart failure, Parkinson's disease, inflammatory bowel disease, and Alzheimer's disease.
As mentioned above, most of these inflammatory complex modulator new drugs have not achieved success in clinical trials, and the reason for this is known to be that the new drug targets alone do not effectively and simultaneously suppress the various pro-inflammatory pathways that activate the NLRP3 inflammatory complex. there is. In other words, the currently known new drugs that regulate the inflammatory complex, such as P2X7 receptor antagonist, NLRP3 inhibitor, and caspase-1 inhibitor, selectively inhibit inflammatory cytokines triggered by inflammatory activity such as IL-1β and IL-18, but are triggered at the initiation stage of inflammation. There is a limitation in suppressing the inflammatory cytokine TNF-α. This is a basic limitation of new drugs that selectively target only NLRP3 or P2X7, and it can be said that the pharmacological mechanism that selectively blocks only the inflammatory activation stage cannot suppress the inflammatory response through various inflammation bypass pathways. In other words, there are many clinical reports of cases where patient drug responsiveness and anti-inflammatory effects for current inflammatory complex regulator new drugs are not met due to alternative activation of the compensatory bypass pathway.
In addition, it has been revealed that due to the genetic redundancy and polymorphisms inherent in NLRP3 and P2X7, current inflammatory complex modulator new drugs do not produce the targeted drug response rates in actual clinical trials. Since it exists in the similar NLRP inflammasome group, which has the same protein domain as the NLPR3 inflammasome, this is the reason that new drugs for controlling the inflammasome do not show sufficient effectiveness.
Hundreds to thousands of SNPs (single nucleotide polymorphisms) have been identified in the P2X7 protein and NLRP3 protein, and individual genetic diversity is very high. As a result, there are often large individual differences in drug response rate and effectiveness, and new drugs targeting these proteins are often individualized. It is unlikely that it will become a treatment with broad efficacy without deviation. As described above, the new drugs targeting inflammatory complexes developed to date, such as P2X7 receptor antagonist, NLRP3 inhibitor, and caspase-1 inhibitor, can be said to have many limitations in achieving the desired clinical efficacy.
In the present invention, in order to overcome the shortcomings of existing inflammatory complex-targeting new drugs, we developed a GPCR19-targeted therapeutic agent that regulates the P2X7R-inflammatory complex at the upstream level. GPCR19 is mainly expressed at a high level in innate immune cells, and because it selectively induces an immune cell-mediated anti-inflammatory effect, it has the advantage of having low non-specific side effects affecting normal cells. This is considering the fact that the target receptors of steroid drugs, which are existing anti-inflammatory drugs, are distributed throughout the body, so that in addition to the pharmacological action on the target, a wide range of systemic reactions are induced, and as a result, systemic metabolic side effects, increased risk of infection, and risk of highly carcinogenic side effects have been reported. In this case, it is believed that GPCR19-targeted new drugs will have great advantages in terms of safety.
To date, drugs targeting GPCR19 include TUDCA, INT-747 (Obeticholic acid, OCA), and INT-777 (S-EMCA). However, how efficiently they suppress inflammatory complexes has not been reported in detail. All of these are bile acid derivatives and have been reported as agonists of GPCR19, but so far, they have mainly been studied on the mechanism of suppressing inflammation by increasing cAMP production and inhibiting NF-kB. Clinical trials are currently underway for TUDCA for diseases such as type 2 diabetes, ulcerative colitis, and Lou Gehrig's disease, and for INT-747 for diseases such as biliary cirrhosis, non-alcoholic steatohepatitis, and liver cirrhosis. In the case of GPCR19-targeted treatments developed to date, there are no new drugs yet that have proven efficacy in clinical trials. In the case of the most recently developed new drugs, there are cases where phase 3 clinical trials targeting inflammatory diseases failed because the anti-inflammatory effect was not high.
The reason for the failure of these GPCR19-targeted treatments is that they overlook the fact that the complex of P2X7R and GPCR19 regulates the inflammatory complex. In other words, without an accurate review of the anti-inflammatory mechanism of GPCR19, new drugs were screened using cell lines that artificially highly expressed GPCR19. This was done through an artificial system that does not correctly reflect the initiation and activation stage of inflammation through GPCR19-P2X7R in the body. This is because it is a screened low-molecular-weight compound. Therefore, the present invention, which improves the drug screening system, overcomes existing failure cases. In the present invention, based on the understanding of the signaling system via the GPCR19-P2X7R-NLRP3 axis, we invented a small molecule compound with a wide range of anti-inflammatory effects that can block both the initiation and activation stages of inflammation and can simultaneously inhibit the cAMP pathway and NRLP pathway.
Bile acid is known as a GPCR19 modulator. Bile acids are amphipathic molecules that have both hydrophobic and hydrophilic regions. Looking at the production process of bile acids, cholesterol is used as a precursor and primary bile acids are produced by cytochrome P450 enzyme in the liver in the form of cholic acid and chenodeoxyholic acid, and later, by combining with taurine and glycine by hepatocytes, it becomes more hydrophilic and moves to the intestines, where it is changed into secondary bile acid by intestinal microorganisms. Secondary bile acids are reabsorbed into the liver through liver-intestinal circulation and move to various tissues through blood vessels to perform various physiological functions. Specifically, it plays a role in digesting fat through its amphipathic properties, inhibiting the overgrowth of harmful intestinal microorganisms through acidity, and excreting cholesterol during the intestinal circulation process. In addition, it is known to transmit signals through receptors such as farnesoid X receptor (FXR), a cell nuclear receptor, and cell membrane GPCR19. Specifically, bile acids bound to the FXR plays a role in suppressing gluconeogenesis and lipogenesis in the liver, and it bound to GPCR19 plays a role in promoting insulin secretion and suppressing cytokine secretion. In particular, because of that the bile acid bound to GPCR19 suppresses the inflammatory response, researches have been conducted on the treatment of diseases such as skin, nerves, stomach, intestines, liver, joints, etc. related to inflammation and autoimmune diseases using bile acids as a treatment.
Looking at the chemical structure of bile acid, it is a steroid structure with four rings and has the following chemical formula. Types of bile acids vary greatly depending on the differences of hydroxyl group position, steric position, number of hydroxyl groups, and etc. The main bile acids in the human body include cholic acid, glycocholic acid, deoxycholic acid, Lithocholic acid, etc. In addition, bile acids can be modified by the reactivity of the hydroxy group or carboxyl group, and due to amphiphilicity, chirality, etc., they are being used not only in the pharmaceutical field but also in various fields such as solution processing materials, thin films, and surfactants.
Taurine (or 2-aminoethanesulfonic acid) is an organic compound and a type of amino acid present in the cells and tissues of mammals, including humans. Taurine is rarely used in protein synthesis and mostly exists in the form of free amino acids, and is present in high concentrations in organs such as the brain, heart, liver, and kidneys, as well as in the skeleton and muscles.
Taurine has an inhibitory effect on the sympathetic nerves of the brain due to its structural characteristics of the J-amino acid of the sulfonic acid group. It is known that taurine is effective in stabilizing blood pressure and other vascular diseases, preventing strokes, and suppressing the production of low-density lipoprotein cholesterol. However, since taurine is difficult to manufacture its derivatives or compositions, taurine is generally used as a raw material. However, taurine can combine with cholic acid, a type of bile acid, to form taurocholic acid, which produces crystalline bile acid that is involved in emulsification of fat.
In this regard, Korean Patent No. 10-1778687 discloses a deoxycholate-based amphipathic compound, and Korean Patent Publication No. 10-1994-0021065 discloses a taurine-bile acid derivative having therapeutic effects.
However, in the case of taurine, it is difficult to form a derivative of taurocholic acid, so there are almost no derivatives of taurocholic acid, and little is known about the therapeutic effect of using it. Accordingly, the present inventors made efforts to produce an inflammatory complex and TNF-α production inhibitor showing excellent effects. As a result, they disclosed that it is possible to produce the compounds of which a novel bile acid derivative and a taurine derivative are covalently bonded, and so a novel taurine-bile acid derivative compound is developed. The present invention is completed by synthesizing it and discovering its therapeutic use.
The present invention relates to a novel compound which is capable of simultaneously controlling the GPCR19-P2X7R-NLRP3 signaling system and the cAMP signaling system and a method for producing the same. Technical challenge of the present invention is to solve the problems of the difficult manufacturing process of the compounds containing conventional taurine derivatives, and a low yield rate and purity.
In addition, the aim of the present invention is to provide new compounds that can be developed as a therapeutic agent by disclosing that the novel compounds synthesized by the method according to the present invention inhibit the production of TNF-α and IL-1β caused by the activation of inflammatory complexes, which plays in an important role in the pathology of various inflammatory diseases, and by showing that the compounds have a useful therapeutic effect.
In order to achieve the above object, the present invention provides a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
wherein,
R1, R2, R3 and R4 are each independently H, halo, C1-5 alkyl, OH, or ═O,
X is substituted or unsubstituted C1-10 alkylene,
wherein when X is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-10 alkyl, halo, OH, SH, NH2, CONH2, or COOH,
A is C1-10 alkylene, C1-10 heteroalkylene, C1-10 alkenylene, C1-5 alkynylene, C3-8 cycloalkylene, C3-8 heterocycloalkylene, C6-20 arylene, C6-20 heteroarylene, —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5) (R6), —CH(R5) (OR6), —CH(OR5) (OR6), —CH(R5) (SR6), or —CH(SR5) (SR6);
R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C6-20 heteroaryl, substituted or unsubstituted C1-10 alkyl-C6-20 cycloalkyl, substituted or unsubstituted C1-10 alkyl-C6-20 heterocycloalkyl, substituted or unsubstituted C1-10 alkyl-C6-20 aryl or substituted or unsubstituted C1-10 alkyl-C6-20 heteroaryl,
wherein, when R5 is substituted, one or more hydrogen(s) is(are) linear
one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, —O, ORa, SRa, N(Ra)2, or CON(Ra)2, Ra is H or C1-5 alkyl,
R6 is bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, substituted or unsubstituted C6-20 arylene, or substituted or unsubstituted C6-20 heteroarylene,
wherein, if R6 is substituted, one or more hydrogen(s) is(are) substituted with ═O, linear or branched C1-10 alkyl, C0-10alkyl-C6-20aryl, C0-10alkyl-OH, C0-10alkyl-NH2, C0-10alkyl-SH, or C0-10alkyl-CONH2; or R5 and R6 together form C3-20 cycloalkylene, C3-20 heterocycloalkylene, C6-20 arylene or C6-20 heteroarylene;
Y combines directly with A or with R6, and is H, —(CH2)nCH3, —(CH2)nCOOH, (CH2)nOH—(CH2)nSO3H, —(CH2)nOSO3H, —(CH2)nPO3H2, —(CH2)nOPO3H2, —(CH2)nSO3NH2, —(CH2)nCONH2, or —(CH2)nC(O)SO3H,
wherein n is an integer from 0 to 10.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, OH, ═O or C1-5 alkyl.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, or OH, and wherein contains at least one OH.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, OH, ═O or C1-5 alkyl, and wherein contains at least one or more ═O or C1-5 alkyl.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, or OH.
In one aspect of the invention, R1, R3 and R4 are OH, and R2 is H.
In one aspect of the invention, R1 and R2 are H, and R3 and R4 are OH.
In one aspect of the invention, R1, R2 and R4 are H, and R3 is OH.
In one aspect of the invention, R1, R2 and R4 are H, and R3 is ═O.
In one aspect of the invention, R1 and R3 are OH, and R2 is C2 alkyl.
In one aspect of the invention, R1, R3 and R4 are OH, R2 is C2 alkyl.
In one aspect of the invention, X is substituted or unsubstituted C1-4 alkylene, and if substituted, one or more hydrogen(s) is(are) linear or branched C1-4 alkyl. In one specific aspect of the invention, X is unsubstituted C1-4 alkylene.
In one aspect of the invention, A is —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5)(R6), —CH(R5) (OR6), —CH(OR5) (OR6), —CH(R5)(SR6), or —CH(SR5)(SR6). In one specific aspect of the invention, A is —NR5R6C(O)—, —C(O)NR5R6, or —CH(R5)(R6).
In one aspect of the invention, R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C1-10alkyl-C6-20 aryl or substituted or unsubstituted C1-10alkyl-C6-20 heteroaryl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, ═O, ORa, SRa, N(Ra)2, or CON(Ra)2, Ra is H or C1-5 alkyl.
In one aspect of the invention, R5 is H, or substituted or unsubstituted C1-10 alkyl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with ═O, OH, SH, NH2, or CONH2.
In one aspect of the invention, R5 is substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl or substituted or unsubstituted C6-20 aryl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with ═O, OH, SH, NH2, or CONH2.
In one aspect of the invention, R5 is unsubstituted C3-10 cycloalkyl, unsubstituted C3-10 heterocycloalkyl or unsubstituted C6-10 aryl.
In one aspect of the invention, R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, or substituted or unsubstituted C6-20 arylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with ═O, linear or branched C1-10 alkyl, C0-10alkyl-C6-20aryl or C0-10alkyl-OH.
In one aspect of the invention, R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, or substituted or unsubstituted C6-20 arylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, C0-5 alkyl-OH, C6-20aryl or CH2—C6-20aryl.
In one aspect of the invention, R6 is a bond.
In one aspect of the invention, R6 is substituted or unsubstituted C1-5 alkylene, wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, C0-3 alkyl-OH, C6 aryl or CH2—C6 aryl.
In one aspect of the invention, R5 and R6 together form C3-10 cycloalkylene, C3-10 heterocycloalkylene, C6-10 arylene or C6-10 heteroarylene.
In one aspect of the invention, R5 and R6 together form
In one aspect of the invention, Y is H, —(CH2)nCH3, —(CH2)nCOOH, —(CH2)nOH, —(CH2)nSO3H or —(CH2)nOSO3H, n is an integer from 0 to 10.
In one aspect of the invention, Y is —(CH2)nSO3H, n is an integer from 0 to 5.
Further, the present invention provides a pharmaceutical composition for treating inflammatory diseases containing the above compound or a pharmaceutically acceptable salt thereof.
The present invention relates to a novel compound for inhibiting TNF-α production and inflammatory complex activity and a method for producing the same, and the compound according to the present invention exhibits a useful anti-inflammatory activity and it can be developed as a treatment measures for the related inflammatory diseases.
The present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
Hereinafter, the present invention is described in detail.
In the present invention, the compound represented by Formula 1 corresponds to a conjugate obtained by reacting a bile acid derivative with a taurine derivative. Bile acid derivatives refer to derivatives of the following structural formula, and the position of each carbon atom is indicated by a commonly used method.
In the present invention, in the bile acid derivative, some of the H atoms substituted on the carbon ring may be substituted with other substituents. When substituted, for example, it may be substituted with C1-5 alkyl, hydroxy, oxo (═O), etc. Examples of substituted structures include Deoxycholic acid, Lithocholic acid, Dehydrolithocholic acid, Obeticholic acid, INT-777, Cholic acid, and the like. However, this is an illustrative example and is not limited to this.
As used herein, “substituted or unsubstituted” refers to an atom that may be substituted or unsubstituted, “substituted” refers to a group having one or more substituents, and a substituent refers to a chemical moiety covalently bonded to the group. Alternatively, “unsubstituted” means that the chemical part is changed directly at the corresponding substituted part without having a substituent.
In this specification, “halo” refers to elements belonging to group 17, such as fluorine, chlorine, bromine, iodine, and the like.
In this specification, “alkyl” refers to a chemical moiety obtained by removing the H atom from the carbon atom of an aliphatic or alicyclic, saturated or unsaturated (unsaturated, fully unsaturated) carbonized H compound, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and the like.
In this specification, “alkylene” is a divalent chemical moiety obtained by removing one more H atom from the alkyl, and does not include the removal of two carbon atoms from one carbon.
In this specification, “heteroalkyl” refers to alkyl containing one or more hetero atoms, and “heteroalkylene” refers to alkylene containing one or more hetero atoms.
In the present invention, “cycloalkyl” refers to an alkyl group, which is a cyclyl group, and refers to a chemical moiety obtained by removing the H atom from an alicyclic ring atom. Examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclohexene, and the like.
As used herein, “heterocycloalkyl” means cycloalkyl containing one or more hetero atoms.
As used herein, “aryl” refers to a chemical moiety obtained by removing the H atom from the aromatic ring atom of an aromatic compound having a ring atom.
In the present invention, “heteroaryl” means aryl containing one or more hetero atoms. Examples include pyridine, pyrrolyl, quinoline, pyridyl, pyrimidinyl, and the like.
As used herein, “branched” means having one or more branched forms, and branching is not limited to carbon and means that it can bind to carbon.
As used herein, “linear” means not having a branched shape.
In this specification, a prefix (e.g., C1-12, C3-8, etc.) refers to the number of ring atoms or a range of the number of ring atoms, regardless of whether they are carbon atoms or hetero atoms. For example, the term “C3-6 heterocycloalkyl” used herein refers to a heterocycloalkyl group having 3 to 6 ring atoms. Additionally, for example, the term “C1-10 alkyl-C6-20 aryl” used herein refers to a form in which C1-10 alkyl and C6-20 aryl are sequentially bonded.
In this specification, isomers are not excluded unless otherwise specified.
The present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
wherein,
R1, R2, R3 and R4 are each independently H, halo, C1-5 alkyl, OH, or ═O,
X is substituted or unsubstituted C1-10 alkylene,
wherein when X is substituted, one or more hydrogens are substituted with linear or branched C1-10 alkyl, halo, OH, SH, NH2, CONH2, or COOH,
A is C1-10 alkylene, C1-10 heteroalkylene, C1-10 alkenylene, C1-5 alkynylene, C3-8 cycloalkylene, C3-8 heterocycloalkylene, C6-20 arylene, C6-20 heteroarylene, —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5)(R6), —CH(R5) (OR6), —CH(OR5) (OR6), —CH(R5) (SR6), or —CH(SR5) (SR6);
R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C6-20 heteroaryl, substituted or unsubstituted C1-10 alkyl-C6-20 cycloalkyl, substituted or unsubstituted C1-10 alkyl-C6-20 heterocycloalkyl, substituted or unsubstituted C1-10alkyl-C6-20 aryl or substituted or unsubstituted C1-10alkyl-C6-20 heteroaryl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, ═O, ORa, SRa, N(Ra)2, or CON(Ra)2, and Ra is H or C1-5 alkyl,
R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, substituted or unsubstituted C6-20 arylene, or substituted or unsubstituted C6-20 heteroarylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with ═O, linear or branched C1-10 alkyl, C0-10alkyl-C6-20aryl, C0-10alkyl-OH, C0-10alkyl-NH2, C0-10alkyl-SH, or C0-10alkyl-CONH2; or R5 and R6 together form C3-20 cycloalkylene, C3-20 heterocycloalkylene, C6-20 arylene or C6-20 heteroarylene;
Y combines directly with A or with R6, and is H, —(CH2)nCH3, —(CH2)nCOOH, —(CH2)nOH—(CH2)nSO3H, —(CH2)nOSO3H, —(CH2)nPO3H2, —(CH2)nOPO3H2, —(CH2)nSO3NH2, —(CH2)nCONH2, or—(CH2)nC(O) SO3H,
wherein n is an integer from 0 to 10.
In one aspect of the invention, Formula 1 can be specifically expressed as the following Formula 2.
wherein, R1, R2, R3, R4, X, A and Y are as the same as defined above.
In one aspect of the invention, the compound or pharmaceutically acceptable salt thereof includes a compound expressed more specifically as Formula 3 below.
In addition, more specifically, the compound or a pharmaceutically acceptable salt thereof includes a compound represented by Formula 4 below.
In Formula 3 and 4, R1, R2, R3, R4, R5, R6, X, and Y are as the same defined above.
In one specific aspect of the invention, R1, R2, R3 and R4 are each independently H, OH, ═O or C1-5 alkyl.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, or OH, wherein contains at least one or more OH.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, OH, —O or C1-5 alkyl, wherein contains at least one or more ═O or C1-5 alkyl.
In one aspect of the invention, R1, R2, R3 and R4 are each independently H, or OH.
In one aspect of the invention, R3 is OH.
In one aspect of the invention, R1 and R3 are OH.
In one aspect of the invention, R3 is ═O.
In one aspect of the invention, R1 and R3 are OH, and R2 is C2 alkyl.
In one aspect of the invention, R1, R3 and R4 are OH, and R2 is C2 alkyl.
In one aspect of the invention, R1, R3 and R4 are OH, and R2 is H.
In one aspect of the invention, R1 and R2 are H, R3 and R4 are OH.
In one aspect of the invention, R1, R2 and R4 are H, and R3 is OH.
In one aspect of the invention, R1, R2 and R4 are H, R3 is ═O.
In one aspect of the invention, R1 and R3 are OH, R2 is C2 alkyl, and R4 is H.
In one aspect of the invention, R1, R3 and R4 are OH, and R2 is C2 alkyl.
In one aspect of the invention, the compounds or pharmaceutically acceptable salts thereof include compounds represented by the following Formulas 5 to 10, and more specifically, Formulas 5-2 to 10-2.
wherein, X, A and Y are as the same defined above.
In one aspect of the invention, X is substituted or unsubstituted C1-4 alkylene, if substituted, one or more hydrogen(s) is(are) linear or branched C1-4 alkyl.
In one aspect of the invention, X is unsubstituted C1-4 alkylene.
In one aspect of the invention, A is —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5)(R6), —CH(R5) (OR6), —CH(OR5) (OR6), —CH(R5) (SR6), or —CH(SR5) (SR6).
In one aspect of the invention, A is —NR5R6C(O)—, —C(O)NR5R6, or —CH(R5)(R6),
In one aspect of the invention, R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C1-10alkyl-C6-20 aryl or substituted or unsubstituted C1-10alkyl-C6-20 heteroaryl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, ═O, ORa, SRa, N(Ra)2, or CON(Ra)2, Ra is H or C1-5 alkyl.
In one aspect of the invention, R5 is H, or substituted or unsubstituted C1-10 alkyl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with ═O, OH, SH, NH2, or CONH2.
In one aspect of the invention, R5 is substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl or substituted or unsubstituted C6-20 aryl,
wherein R5 is substituted, one or more hydrogen(s) is(are) substituted with ═O, OH, SH, NH2, or CONH2.
In one aspect of the invention, R5 is unsubstituted C3-10 cycloalkyl, unsubstituted C3-10 heterocycloalkyl or unsubstituted C6-10 aryl.
In one aspect of the invention, R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, or substituted or unsubstituted C6-20 arylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with ═O, linear or branched C1-10 alkyl, C0-10alkyl-C6-20aryl or C0-10alkyl-OH.
In one aspect of the invention, R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, or substituted or unsubstituted C6-20 arylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, C0-5 alkyl-OH, C6-20aryl or CH2—C6-20aryl.
In one aspect of the invention, R6 is a bond.
In one aspect of the invention, R6 is substituted or unsubstituted C1-5 alkylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, C0-3 alkyl-OH, C6 aryl or CH2—C6 aryl.
In one aspect of the invention, R5 and R6 together form C3-10 cycloalkylene, C3-10 heterocycloalkylene, C6-10 arylene or C6-10 heteroarylene.
In one aspect of the invention, R5 and R6 together form
In one aspect of the invention, Y is H, —(CH2)nCH3, —(CH2)nCOOH, —(CH2)nOH, —(CH2)nSO3H or —(CH2)nOSO3H, and n is an integer from 0 to 10.
In one aspect of the invention, Y is —(CH2)nSO3H, and n is an integer from 0 to 5.
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
[The Following Compounds and their Pharmaceutically Acceptable Salts]
The present invention includes not only the compound represented by Formula 1, but also pharmaceutically acceptable salts thereof, and possible solvates, hydrates, racemates, or stereoisomers that can be prepared therefrom.
In one aspect of the invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof.
(wherein, Na+ can be replaced by other pharmaceutically acceptable salts)
The compound represented by Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as the salt. Acid addition salts are obtained from an inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, and hydroxy alkanoates and non-toxic organic acids such as alkanedioates, aromatic acids, aliphatic and aromatic sulfonic acids. These pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, and iodine, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, methylbenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like.
The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving taurodeoxycholic acid represented by Formula 1 in an excessive amount of aqueous acid, and dissolving this salt cab be produced by precipitation using a water-miscible organic solvent, such as methanol, ethanol, acetone or acetonitril. Additionally, this mixture can be prepared by evaporating the solvent or excess acid and drying it, or by suction filtering the precipitated salt.
Additionally, a pharmaceutically acceptable metal salt can be prepared using a base. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically appropriate to manufacture sodium, potassium or calcium salts as metal salts, and more specifically, it is suitable to manufacture sodium salts. Additionally, the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (e.g., silver nitrate).
In one specific aspect of the invention, salt may be selected from the group consisting of Sodium, Hydrogen, Potassium, Magnesium, Calcium, Aluminum, Chloride, Hydrochloride, Sulfate, Carbonate, Nitrate, Phosphate, Ferrous salt, tartrate, Arginine, Benzathine, Chloroprocaine, Choline, Diethanolamine, thanolamine, Ethylenediamine, Histidine, Lithium, Lysine, Meglumine, Procaine, Triethylamine, Zinc, Acetate, Aspartate, Benzensulfonate, Benzoate, Besylate, Bicarbonate, Bitartrate, Bromide, Camsylate, Citrate, Decanoate, Edetate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycolate, Glycollylarsanilate, Caproate, Hexanoate, Hexylresorcinate, Hydrabamine, Hydroxynaphthoate, Iodide, Isethionate, Lactate, Lactobionate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Octanoate, Oleate, Pamoate, Pantothenate, Polygalacturonate, Propionate, Salicylate, Stearate, Subacetate, Succinate, Teoclate, Tosylate and Triethiodide. In one specific aspect of the invention, the pharmaceutically acceptable salt may be Sodium salt.
In one aspect of the invention, the compound or a pharmaceutically acceptable salt thereof may additionally include amino acids, peptides, saccharides, polysaccharides, or one or more conjugates thereof.
Additionally, the present invention provides a pharmaceutical composition containing the above compound or a pharmaceutically acceptable salt thereof.
Additionally, the present invention provides a pharmaceutical composition for treating inflammatory diseases containing the above compound or a pharmaceutically acceptable salt thereof.
The present invention also relates to a treatment method of administering the composition to a subject.
Additionally, the present invention relates to a pharmaceutical composition for treating inflammatory diseases by administering the composition to a subject.
In one aspect of the invention, the pharmaceutical composition may further include pharmaceutically acceptable ingredients. Examples of pharmaceutically acceptable ingredients may further include ARB (Angiotensin Receptor Blocker)-a compositions for the treatment of essential hypertension, ACEI (Angiotensin Converting Enzyme Inhibitor), CCB (Calcium Channel Blocker), BB (Beta Blocker), Diuretics, Biguanides-a composition for treating type 2 diabetes, SU (Sulfonyl Urea), Meglitinides, TZD (Thiazolidinedione), DPP-4i (Dipeptidyl Peptidase-4 inhibitor), SGLT-2i (Sodium Glucose Co-Transporter 2 inhibitor, GLP-1RA (Glucagon Like Peptide 1 Receptor Agonist), Acetaminophens-a composition for treating acute bronchitis, NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Penicilins, Cephalosporins, Monobactams, Carbapenems, Polymyxins, Aminoglycosides, Macrolides, Fluoroquinolones, Glycopeptides, HMG-CoA reductase inhibitors (β-hydroxy β-methylglutaryl-CoA reductase inhibitor)-a composition for treating dyslipidemia, PCSK9 inhibitors (Proprotein Convertase Subtilisin/Kexin type9 inhibitor), Fibrates, Resins, Omega-3, PPI (Proton Pump Inhibitor)-a composition for treating GERD, H1-antagonist, H2-antagonist-a composition for treating allergic rhinitis, Corticosteroids, LTRA (Leukotriene receptor antagonist), α2-agonist, mast cell stabilizer, Anticholinergic agents, Cholinesterase inhibitor-a composition for treating dementia, NMDA receptor antagonist, antipsychotic agents, antidepressant, Acetaminophen-a commposition for treating osteoarthritis, NSAIDs, Tramadol, 5-HT3 agonist-a composition for treating migraine, Ergot alkaloids.
The route of administration of the compound of the present invention may be, for example, oral or parenteral route. Here, parenteral refers to a broad route of administration, for example, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intranasal, sublingual, intrathecal, inhalation, ocular, rectal, vaginal, intraventricular administration, and the like.
When formulating the composition, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and these solid preparations is prepared by mixing one or more compounds according to the present invention with at least one or more excipients, such as starch, calcium carbonate, sucrose, lactose, or gelatin. Additionally, in addition to simple excipients, lubricants such as magnesium styrate, talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, or syrups, and in addition to the commonly used simple diluents such as water and liquid paraffin, they can contain various excipients such as wetting agents, sweeteners, fragrances, preservatives, and the like.
Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycerol, gelatin, and the like, can be used.
The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level can be determined by the type, severity, and activity of the patient's disease, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the field of medicine. The composition of the present invention can be administered as an individual treatment or in combination with other treatments, and can be administered sequentially or simultaneously with conventional treatments, and can be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.
Specifically, the effective amount of the compound according to the present invention may vary depending on the patient's age, gender, and weight, and is generally 0.01 mg to 100 mg per kg of body weight, more specifically 0.1 mg to 15 mg per kg of body weight daily or every other day, or divided into 1 to 3 doses per day. However, since it may increase or decrease depending on the route of administration, severity, gender, weight, age, and the like, the above dosage does not limit the scope of the present invention in any way.
In the present invention, for preparing the compound of Formula 1, bile acids or derivatives thereof can be used freely, whether isolated from animal carcasses, such as sheep, dogs, goats or rabbits, commercially available, or synthesized.
Hereinafter, the present invention is described in detail through examples and experimental examples.
However, the following examples and experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.
Amine (1) was added to 2.25 mL (5.0 mmol) of vinylsulfonic acid sodium salt (2) solution (25 wt %, in H2O), and the resulting mixture was stirred at 100° C. for 48 hours. After cooling, the reaction mixture was concentrated under reduced pressure and coevaporated with acetonitrile to obtain sodium sulfonate compound (A1).
2.1 mL (35.0 mmol) of carbon disulfide in a mixture of 7.0 mmol of 2-aminoethan-1-ol (3) and 35.0 mL (35.0 mmol) of potassium hydroxide (1M in H2O) was added and the resulting mixture was heated at 100° C. for 16 hours. After cooling to room temperature, the mixture was extracted with dichloromethane (3×20 mL). The combined organic layer was dried with sodium sulfate, and the solvent was completely removed under reduced pressure to obtain thiazolidine-2-thione compound (B1).
7.0 mL (68.5 mmol) of hydrogen peroxide solution (30%) was dissolved in 35.0 mL (928 mmol) of formic acid at 0° C., and stirred at room temperature for 1 hour to obtain peroxyformic acid. The peroxyformic acid solution was cooled back to 0° C., 7.0 mmol of the thiazolidine-2-thione compound was added little by little, the resulting solution was stirred, and heated to room temperature. After 18 hours, the mixture was concentrated under reduced pressure and co-evaporated with acetonitrile. The obtained raw material was crystallized with ethanol and diethyl ether at 4° C. to obtain pure sulfonic acid (B2).
2.08 mL (15.0 mmol) of triethylamine and 35 mL of dichloromethane containing 10.0 mmol of tert-butyl(2-hydroxyethyl)carbamate (4) was added to the solution. The mixed solution was cooled to 0° C., and 0.93 ml (12.0 mmol) of mesyl chloride was added dropwise. The resulting mixture was stirred for 2 hours while slowly heating to room temperature. Saturated sodium bicarbonate was added to separate the layers, and the aqueous layer was extracted with dichloromethane (2×30 mL). The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2-((tert-butoxycarbonyl)amino)ethyl methane sulfonate (C1) was obtained.
Prepared by dissolving 2.28 g (20.0 mmol) of potassium thioacetate and 10.0 mmol of 2-(tert-butoxycarbonyl)amino)ethyl methane sulfonate (C1) in 50 mL of dry anhydrous N,N-DMF, and the resulting mixture was stirred at 65° C. for 16 hours. Afterwards, 50 mL of water and 50 mL of ethyl acetate were added to separate the layers. The organic layer was washed with 80% saturated brine (4×30 mL). Afterwards, the organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography to obtain S-(2-((tert-butoxycarbonyl)amino)ethyl) ethane thioate (S-(2-((tert-butoxycarbonyl)amino) ethyl) ethane thioate (C2) was obtained.
4.25 mL (41.6 mmol) of hydrogen peroxide solution (30%) was dissolved in 20.8 mL (928 mmol) of formic acid at 0° C., and stirred at room temperature for 1 hour to obtain peroxyformic acid. The peroxyformic acid solution was cooled back to 0° C., 4.2 mmol of S-(2-((tert-butoxycarbonyl)amino)ethyl)ethane thioate (C2) was added dropwise, the resulting solution was stirred, and the resulting solution was stirred and cooled to room temperature. heated. After 18 hours, the mixture was concentrated under reduced pressure and co-evaporated with ethanol. The residue was washed once with DCM/EtOH and once with DCM to obtain pure sulfonic acid (C3).
In 1 mL of dry anhydrous N,N-DMF containing 0.134 mmol of cholic acid and its derivatives (CA1-7), 0.147 mmol of taurine derivatives (A1, B2, C3) prepared in <Example 1-1> to <Example 1-3>, triethylamine 0.024 mL (0.174 mmol) and N-Ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline (EEDQ) 0.043 g (0.0174 mmol) was added, and the mixed solution was stirred at 90° C. for 70 minutes. After cooling, the mixture was flushed with Dowex and rinsed with 4-6 mL of methanol. Afterwards, the mixture was concentrated and purified by basic preparative liquid chromatography-mass spectrometry (LCMS) to obtain compounds (NC10XXX to NC50XXX) containing 2-aminoethanesulfonic acid.
The compounds (NC10XXX˜NC50XXX) obtained in <Example 2-1> were dissolved in 1 mL of MeCN/H2O (9:1), and an equimolar amount of NaOH aqueous solution (0.1 M) was added. The resulting solution was concentrated in vacuum to obtain Na-salt compounds (NC10XXX˜NC50XXX, Na-salt).
Compound 1 was prepared by the preparation method of <Example 1> and <Example 2> above. Specifically, 400 mg (10 mmol) of NaOH was dissolved in 40 mL of 95% ethanol, 1.11 q (10 mmol) of aminomethanesulfonic acid was added, and the mixture was heated to 50° C. and stirred for 30 minutes. This was cooled to room temperature, 4.12 q (10.4 mmol) of deoxycholic acid (DCA) and 5.0 q (20.2 mmol) of EEDQ were added, washed with 5 mL of ethanol, heated to 40° C., and stirred for 15 hours. Afterwards, it was cooled to room temperature and stirred for 1 hour. The solvent was evaporated, 50 mL of acetone was added, and ultrasound was applied to obtain a solid. Afterwards, it was filtered, washed with acetone, and dried under vacuum for 5 hours to obtain 0.99 q of Compound 1. (yield 19%)
Compound 2 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 1.39 g (10 mmol) of 3-Amino-1-propanesulfonic acid, 400 mg (10 mmol) of NaOH and 5.0 g (20.2 mmol) of EEDQ.
Compound 3 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 1.73 g (10 mmol) of 4-aminobenzenesulfonic acid, 400 mg (10 mmol) of NaOH, and 5.0 g (20.2 mmol) of EEDQ.
Compound 4 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 2.07 g (10 mmol) of 2-(Cyclohexylamino)ethanesulfonic acid, 400 mg (10 mmol) of NaOH and 5.0 g using (20.2 mmol) of EEDQ. (yield 51%)
Compound 5 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 1.82 g (10 mmol) of N-(2-Acetamido)-2-aminoethanesulfonic acid, 400 mg (10 mmol) of NaOH and 5.0 g (20.2 mmol) of EEDQ. (yield 79.0%)
Compound 6 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 2.5 g (10 mmol) of N-Methyltaurine sodium salt, 400 mg (10 mmol) of NaOH, and 5.0 g (20.2 mmol) of EEDQ.
Compound 7 was prepared in the same manner as in the above example using 4.12 g (10.4 mmol) of deoxycholic acid (DCA), 1.41 g (10 mmol) of 2-Aminoethyl hydrogen sulfate, and 5.0 g (20.2 mmol) of EEDQ.
Compound 8 was prepared in the same manner as in the above example using 0.210 g (0.54 mmol) of deoxycholic acid (DCA), 96.6 mg (0.5 mmol) of 2-(Piperidin-4-yl)ethane-1-sulfonic acid, 20 mg (0.5 mmol) of NaOH, and 0.250 g (1.0 mmol) of EEDQ. (yield 74.6%)
Compound 9 was prepared in the same manner as in the above example using 0.205 g (0.52 mmol) of Deoxycholic acid (DCA), 83.1 mg (0.5 mmol) of Piperazine-1-sulfonic acid, 20 mg (0.5 mmol) of NaOH and 0.250 g (1.0 mmol) of EEDQ. (yield 56.5%)
Compound 10 was prepared in the same manner as in the above example using 0.205 g (0.52 mmol) of deoxycholic acid (DCA), 97.1 mg (0.5 mmol) of 2-(piperazin-1-yl)ethane-1-sulfonic acid, 20 mg (0.5 mmol) of NaOH and 0.250 g (1.0 mmol) of EEDQ. (yield 71.1%)
Compound 11 was prepared in the same manner as in the above example using 0.410 g (1.04 mmol) of deoxycholic acid (DCA), 165 mg (1.0 mmol) of piperidine-4-sulfonic acid, 40 mg (1.0 mmol) of NaOH and 0.500 g (2.0 mmol) of EEDQ. (yield 60.5%)
Compound 12 was prepared in the same manner as in the above example using 0.200 g (0.53 mmol) of Lithocholic acid (LCA), 96.2 mg (0.5 mmol) of 2-(Piperidin-4-yl)ethane-1-sulfonic acid, 20 mg (0.5 mmol) of NaOH, and 0.250 g (1.01 mmol) of EEDQ. (yield 73.2%)
Compound 13 was prepared in the same manner as in the above example using 0.395 g (1.05 mmol) of Lithocholic acid (LCA), 141 mg (1.0 mmol) of 2-Aminoethyl hydrogen sulfate, 40 mg (1.0 mmol) of NaOH and 0.507 g (2.05 mmol) of EEDQ. (yield 61.3%)
Compound 14 was prepared in the same manner as in the above example using 0.395 g (1.05 mmol) of Lithocholic acid (LCA), 139 mg (1.0 mmol) of 3-Amino-1-propanesulfonic acid, 40 mg (1.0 mmol) of NaOH and 0.507 g (2.05 mmol) of EEDQ. (yield 86.6%)
Compound 15 was prepared in the same manner as in the above example using 0.395 g (1.05 mmol) of lithocholic acid (LCA), 173 mg (1.0 mmol) of 4-aminobenzenesulfonic acid, 40 mg (1.0 mmol) of NaOH, and 0.505 g (2.05 mmol) of EEDQ. (yield 70.4%)
Compound 16 was prepared in the same manner as in the above example using 0.395 g (1.05 mmol) of Lithocholic acid (LCA), 207 mg (1.0 mmol) of 2-(Cyclohexylamino)ethanesulfonic acid, 40 mg (1.0 mmol) of NaOH and 0.507 g (2.05 mmol) of EEDQ. (yield 66.3%)
Compound 9 was prepared by the preparation method of <Example 1> and <Example 2> above. Specifically, deoxycholic acid (DCA) 3.92 q (10 mmol), hydroxybenzotriazole (HOBt) 1.42 g (10.5 mmol), N,N′-dicyclohexylcarbodiimide (DCC) 2.17 q (10.5 mmol) were mixed with 30 mL of DMF. To the mixture, 1.41 mL (10 mmol) of N,N-Diethylethylenediamine and 1.15 mL (10.4 mmol) of N-methylmorpholine (N-MMP) were added. This was heated to 40-45° C. and stirred for 1 day. Afterwards, it was cooled to room temperature, filtered and washed with 10 mL of DMF. The solvent was evaporated under reduced pressure, dissolved in 20 mL of 2N HCl and 80 mL of H2O, and washed with 100 mL of ethyl acetate X2. Afterwards, it was neutralized with NaOH until the pH reached 8-9, and NaCl was added to saturate it. It was extracted with 100 mL of dichloromethane X 2, mixed with the organic layer, and dissolved in 10 mL of methanol. Afterwards, it was dried with Na2SO4, filtered and washed with dichloromethane, and the solvent was evaporated. Afterwards, compound 17 was obtained by sequentially filtering and washing using ethanol, 1N HCl ether, and acetone.
Compound 18 was prepared in the same manner as in the above example using 3.92 g (10 mmol) of Deoxycholic acid (DCA), 1.42 g (10.5 mmol) of HOBt, 2.17 g (10.5 mmol) of DCC, 1.30 g (10 mmol) of 4-(2-Aminoethyl)morpholine and 1.06 g (10.4 mmol) of N-MMP.
Compound 19 was prepared in the same manner as in the above example using 3.92 g (10 mmol) of deoxycholic acid (DCA), 1.42 g (10.5 mmol) of HOBt, 2.17 g (10.5 mmol) of DCC, 1.00 g (10 mmol) of 1-Methylpiperazine, and 1.06 g (10.4 mmol) of N-MMP.
The following bile acid derivatives were prepared in the same manner as in the above examples, and the specific chemical structures, NMR data, and MS data of the bile acid derivatives are shown below.
1H NMR (400 MHz. DMSO-d6) δ 8.04 (t, J=6.2 Hz, 1H), 4.45 (s, 1H), 4.22-4.15 (m, 1H), 3.92-3.82 (m, 2H), 3.81-3.76 (m, 1H), 3.41-3.31 (m, 1H), 2.15 (ddd, J=14.1, 10.6, 5.0 Hz, 1H), 2.00 (ddd, J=14.1, 10.2, 6.0 Hz, 1H), 1.86-1.41 (m, 10H), 1.40-0.94 (m, 13H), 0.94-0.85 (m, 4H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C25H42NO6S [M-Na]− 484.3, found 484.6.
1H NMR (400 MHz, DMSO-d6) δ 7.78 (t, J=5.6 Hz, 1H), 4.46 (d, J=4.4 Hz, 1H), 4.19 (d, J=4.1 Hz, 1H), 3.81-3.74 (m, 1H), 3.47-3.32 (m, 1H), 3.08-3.03 (m, 2H), 2.45-2.37 (m, 2H), 2.12-2.00 (m, 1H), 1.93 (ddd, J=13.7, 9.6, 6.4 Hz, 1H), 1.86-0.95 (m, 25H), 0.94-0.85 (m, 4H), 0.84 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.6.
1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 7.56-7.47 (m, 4H), 4.47 (d, J=4.2 Hz, 1H), 4.21 (d, J=3.9 Hz, 1H), 3.83-3.76 (m, 1H), 3.49-3.38 (m, 1H), 2.34 (ddd, J=14.1, 9.7, 4.6 Hz, 1H), 2.20 (ddd, J=14.7, 9.0, 6.5 Hz, 1H), 1.87-1.67 (m, 5H), 1.67-1.41 (m, 5H), 1.41-1.13 (m, 11H), 1.12-0.86 (m, 6H), 0.84 (s, 3H), 0.60 (s, 3H); LCMS (ESI) m/z calcd for C30H44NO6S [M-Na]− 546.3, found 546.6.
1H NMR (400 MHz, DMSO-d6) δ 4.45 (t, J=4.9 Hz, 1H), 4.20 (d, J=4.1 Hz, 1H), 4.15-4.07 (m, 0.5H), 3.83-3.76 (m, 1H), 3.57-3.47 (m, 0.5H), 3.46-3.35 (m, 3H), 2.66-2.54 (m, 2H), 2.33-2.11 (m, 2H), 1.86-0.86 (m, 37H), 0.84 (s, 3H), 0.59 (d, J=1.9 Hz, 3H); LCMS (ESI) m/z calcd for C32H54NO6S [M-Na]− 580.4, found 580.8.
1H NMR (400 MHz, DMSO-d6) δ 7.52 (s, 0.4H) 7.42 (s, 0.6H), 7.11 (s, 0.4H), 6.91 (s, 0.6H), 4.49-4.40 (m, 1H), 4.20 (d, J=4.1 Hz, 0.6H), 4.18 (d, J=4.1 Hz, 0.4H), 3.91 (s, 1H), 3.83-3.71 (m, 2H), 3.61-3.51 (m, 1H), 3.49-3.41 (m, 1H), 3.41-3.31 (m, 1H), 2.69-2.65 (m, 1.2H), 2.59-2.56 (m, 0.8H), 2.49-2.38 (m, 0.6H), 2.33-2.21 (m, 0.6H), 2.21-2.10 (m, 0.4H) 2.07-1.97 (m, 0.4H), 1.87-1.41 (m, 10H), 1.40-0.79 (m, 20H), 0.60 (s, 1.8H), 0.59 (s, 1.2H); LCMS (ESI) m/z calcd for C28H47N2O7S [M-Na]− 555.3, found 555.6.
1H NMR (400 MHz, DMSO-d6) δ4.45 (s, 1H), 4.25-4.16 (m, 1H), 3.79 (s, 1H), 3.55-3.41 (m, 2H), 3.40-3.30 (m, 1H), 2.93 (s, 1.5H), 2.75 (s, 1.5H), 2.69-2.62 (m, 1H), 2.60-2.53 (m, 1H), 2.36-2.10 (m, 2H), 1.86-1.70 (m, 4H), 1.68-1.41 (m, 6H), 1.40-1.11 (m, 11H), 1.09-0.85 (m, 6H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.6.
1H NMR (400 MHz, DMSO-d6) δ 7.85 (t, J=5.6 Hz, 1H), 4.45 (d, J=4.3 Hz, 1H), 4.18 (d, J=4.1 Hz, 1H), 3.82-3.75 (m, 1H), 3.69 (t, J=6.1 Hz, 2H), 3.42-3.31 (m, 1H), 3.19 (q, J=5.9 Hz, 2H), 2.14-2.03 (m, 1H), 1.95 (ddd, J=13.9, 9.7, 6.3 Hz, 1H), 1.86-1.69 (m, 4H), 1.68-1.40 (m, 6H), 1.40-1.09 (m, 11H), 1.08-0.85 (m, 6H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C26H44NO7S [M-Na]− 514.3, found 514.5.
1H NMR (400 MHz, DMSO-d6) δ 4.46 (d, J=4.2 Hz, 1H), 4.34 (d, J=12.9 Hz, 1H), 4.19 (d, J=4.0 Hz, 1H), 3.84-3.75 (m, 2H), 3.42-3.30 (m, 1H), 2.98-2.87 (m, 1H), 2.48-2.36 (m, 3H), 2.34-2.22 (m, 1H), 2.22-2.10 (m, 1H), 1.86-1.41 (m, 15H), 1.40-0.85 (m, 19H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.7.
1H NMR (400 MHz, DMSO-d6) δ 4.45 (d, J=4.2 Hz, 1H), 4.19 (d, J=4.0 Hz, 1H), 3.82-3.75 (m, 1H), 3.48-3.35 (m, 5H), 2.83-2.65 (m, 4H), 2.30 (ddd, J=15.4, 10.3, 5.2 Hz, 1H), 2.17 (ddd, J=15.3, 9.9, 5.9 Hz, 1H), 1.86-1.69 (m, 4H), 1.67-1.41 (m, 6H), 1.39-1.12 (m, 11H), 1.10-0.86 (m, 6H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C28H47N2O6S [M-Na]− 539.3, found 539.5.
1H NMR (500 MHz, CD3OD) δ 3.98-3.94 (m, 1H), 3.61-3.46 (m, 5H), 3.07-2.99 (m, 2H), 2.89-2.82 (m, 2H), 2.56-2.54 (m, 2H), 2.52-2.40 (m, 3H), 2.35-2.27 (m, 1H), 1.96-1.68 (m, 7H), 1.67-1.56 (m, 3H), 1.55-1.23 (m, 11H), 1.22-0.91 (m, 9H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C30H51N2O6S [M-Na]− 567.3, found 567.8.
1H NMR (500 MHz, CD3OD) δ 4.65-4.55 (m, 1H), 4.06-4.04 (m, 1H), 3.97-3.95 (m, 1H), 3.57-3.47 (m, 1H), 3.13 (td, J=13.2, 2.6 Hz, 1H), 2.90 (tt, J=11.7, 3.8 Hz, 1H), 2.69-2.60 (m, 1H), 2.52-2.40 (m, 1H), 2.38-2.26 (m, 1H), 2.23-2.08 (m, 2H), 1.95-1.68 (m, 8H), 1.68-1.55 (m, 4H), 1.55-1.23 (m, 11H), 1.22-1.06 (m, 2H), 1.04 (d, J=6.5 Hz, 3H), 0.98 (td, J=14.1, 3.3 Hz, 1H), 0.93 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.7.
1H NMR (400 MHz, DMSO-d6) δ 4.50 (s, 1H), 4.33 (d, J=13.1 Hz, 1H), 3.80 (d, J=13.4 Hz, 1H), 3.53-3.35 (m, 1H), 2.95-2.89 (m, 1H), 2.48-2.36 (m, 3H), 2.35-2.22 (m, 1H), 2.22-2.11 (m, 1H), 1.96-1.87 (m, 1H), 1.85-1.72 (m, 2H), 1.71-1.43 (m, 10H), 1.42-0.77 (m, 26H), 0.60 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO5S [M-Na]− 550.4, found 550.3.
1H NMR (500 MHz, CD3OD) δ4.31-4.26 (m, 1H), 4.05-4.01 (m, 1H), 3.60-3.49 (m, 1H), 3.46-3.42 (m, 1H), 3.23-3.19 (m, 1H), 2.49-2.08 (m, 2H), 2.03-2.00 (m, 1H), 1.96-1.70 (m, 5H), 1.66-1.57 (m, 2H), 1.51-1.24 (m, 12H), 1.24-1.05 (m, 5H), 1.03-0.93 (m, 7H), 0.694 (s, 1.5H), 0.691 (s, 1.5H); LCMS (ESI) m/z calcd for C26H44NO6S [M-Na]− 498.3, found 498.6.
1H NMR (400 MHz, DMSO-d6) δ 7.80 (t, J=5.6 Hz, 1H), 4.49 (d, J=4.5 Hz, 1H), 3.59-3.24 (m, 1H), 3.05 (q, J=6.6 Hz, 2H), 2.46-2.37 (m, 2H), 2.11-2.01 (m, 1H), 1.99-1.87 (m, 2H), 1.83-1.43 (m, 9H), 1.41-0.96 (m, 17H), 0.95-0.80 (m, 7H), 0.60 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.6.
1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 7.57-7.46 (m, 4H), 4.45 (d, J=4.5 Hz, 1H), 3.42-3.31 (m, 1H), 2.33 (ddd, J=14.7, 9.7, 5.2 Hz, 1H), 2.20 (ddd, J=14.7, 9.3, 6.6 Hz, 1H), 1.97-1.90 (m, 1H), 1.88-1.45 (m, 7H), 1.45-0.97 (m, 17H), 0.97-0.89 (m, 4H), 0.87 (s, 3H), 0.62 (s, 3H); LCMS (ESI) m/z calcd for C30H44NO5S [M-Na]− 530.3, found 530.7.
1H NMR (500 MHz, CD3OD) δ 3.73-3.61 (m, 2H), 3.58-3.47 (m, 1H), 3.08-3.00 (m, 2H), 2.49-2.38 (m, 1H), 2.37-2.25 (m, 1H), 2.05-1.99 (m, 1H), 1.95-1.52 (m, 14H), 1.52-1.05 (m, 21H), 1.04-0.92 (m, 7H), 0.70 (d, J=4.9 Hz, 3H); LCMS (ESI) m/z calcd for C32H4NO5S [M-Na]− 564.4, found 564.6.
1H NMR (500 MHz, CD3OD) δ 3.96 (t, J=3.0 Hz, 1H), 3.58-3.48 (m, 3H), 3.30-3.22 (m, 6H), 2.32 (ddd, J=14.0, 10.6, 4.9 Hz, 1H), 2.16 (ddd, J=14.1, 9.9, 6.2 Hz, 1H), 1.95-1.73 (m, 7H), 1.67-1.56 (m, 3H), 1.56-1.24 (m, 17H), 1.22-1.07 (m, 2H), 1.03 (d, J=6.4 Hz, 3H), 1.01-0.95 (m, 1H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H55N2O3 [M-Cl]+ 491.4, found 491.3.
1H NMR (500 MHz, CD3OD) δ4.12-4.02 (m, 2H), 3.97-3.94 (m, 1H), 3.84-3.73 (m, 2H), 3.65-3.48 (m, 5H), 3.29 (t, J=6.0 Hz, 2H), 3.23-3.12 (m, 2H), 2.33 (ddd, J=13.9, 10.6, 4.7 Hz, 1H), 2.22-2.13 (m, 1H), 1.95-1.73 (m, 7H), 1.67-1.55 (m, 3H), 1.55-1.33 (m, 9H), 1.33-1.23 (m, 2H), 1.23-1.07 (m, 2H), 1.05-0.95 (m, 4H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H53N2O4 [M-Cl]+ 505.4, found 505.3.
1H NMR (500 MHz, CD3OD) δ4.66 (s, 1H), 4.20 (s, 1H), 3.97-3.95 (m, 1H), 3.73-3.36 (m, 4H), 3.28-2.96 (m, 3H), 2.93 (s, 3H), 2.51 (ddd, J=15.7, 10.9, 5.1 Hz, 1H), 2.36 (ddd, J=15.6, 10.5, 5.6 Hz, 1H), 1.95-1.70 (m, 7H), 1.68-1.56 (m, 3H), 1.56-1.23 (m, 11H), 1.23-1.06 (m, 2H), 1.04 (d, J=6.5 Hz, 3H), 1.02-0.95 (m, 1H), 0.94 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H51N2O3 [M-Cl]+ 475.4, found 475.3.
1H NMR (400 MHz, DMSO-d6) δ 7.79 (t, J=5.4 Hz, 1H), 4.47 (s, 1H), 4.22 (s, 1H), 3.78 (s, 1H), 3.41-3.29 (m, 1H), 3.12-3.07 (m, 2H), 2.04 (ddd, J=14.8, 10.1, 5.1 Hz, 1H), 1.97-1.85 (m, 3H), 1.85-1.41 (m, 10H), 1.40-0.93 (m, 13H), 0.93-0.85 (m, 4H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5 [M-Na]− 462.3, found 462.2.
1H NMR (500 MHz, CD3OD) δ3.96 (t, J=3.0 Hz, 1H), 3.58 (t, J=6.3 Hz, 2H), 3.56-3.49 (m, 1H), 3.25 (td, J=6.9, 1.1 Hz, 2H), 2.29-2.20 (m, 1H), 2.15-2.05 (m, 1H), 1.95-1.74 (m, 7H), 1.74-1.66 (m, 2H), 1.65-1.56 (m, 3H), 1.56-1.23 (m, 11H), 1.23-1.06 (m, 2H), 1.05-0.94 (m, 4H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO4 [M-H]− 448.3, found 448.1.
1H NMR (500 MHz, CD3OD) δ7.41-7.34 (m, 1H), 7.34-7.19 (m, 4H), 4.74 (s, 1H), 4.63 (s, 1H), 3.99-3.94 (m, 0.5H), 3.93-3.88 (m, 0.5H), 3.83-3.67 (m, 2H), 3.57-3.46 (m, 1H), 3.10-2.96 (m, 2H), 2.62-2.52 (m, 0.5H), 2.52-2.38 (m, 1H), 2.35-2.25 (m, 0.5H), 1.96-1.68 (m, 7H), 1.68-1.03 (m, 18H), 1.02-0.90 (m, 5H), 0.71 (s, 1.5H), 0.67 (s, 1.5H); LCMS (ESI) m/z calcd for C33H50NO6S [M-Na]− 588.3, found 588.2.
1H NMR (500 MHz, CD3OD) δ3.99-3.93 (m, 1H), 3.89-3.77 (m, 1H), 3.77-3.64 (m, 3H), 3.60-3.44 (m, 3H), 3.15-3.01 (m, 2H), 2.57-2.45 (m, 1H), 2.43-2.30 (m, 1H), 1.96-1.70 (m, 7H), 1.66-1.55 (m, 3H), 1.55-1.24 (m, 11H), 1.23-0.94 (m, 6H), 0.93 (s, 3H), 0.73-0.69 (m, 3H); LCMS (ESI) m/z calcd for C28H48NO7S [M-Na]− 542.3, found 542.4.
1H NMR (500 MHz, CD3OD) δ4.66-4.56 (m, 0.5H), 4.23-4.13 (m, 0.5H), 3.99-3.94 (m, 1H), 3.72-3.65 (m, 1H), 3.65-3.58 (m, 1H), 3.57-3.46 (m, 1H), 3.10-3.01 (m, 2H), 2.51-2.40 (m, 1H), 2.38-2.26 (m, 1H), 1.95-1.69 (m, 7H), 1.67-1.57 (m, 3H), 1.55-1.23 (m, 15H), 1.23-1.07 (m, 4H), 1.06-0.94 (m, 4H), 0.934 (s, 1.5H), 0.932 (s, 1.5H), 0.72 (s, 1.5H), 0.71 (s, 1.5H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.2.
1H NMR (500 MHz, CD3OD) δ4.44 (tt, J=12.2, 4.0 Hz, 0.5H), 4.06-3.91 (m, 3.5H), 3.77-3.62 (m, 2H), 3.56-3.41 (m, 3H), 3.09-3.01 (m, 2H), 2.54-2.43 (m, 1H), 2.36 (ddd, J=14.7, 10.2, 5.8 Hz, 1H), 2.05-1.23 (m, 25H), 1.23-1.02 (m, 5H), 1.01-0.94 (m, 1H), 0.935 (s, 1.5H), 0.931 (s, 1.5H), 0.72 (s, 1.5H), 0.71 (s, 1.5H); LCMS (ESI) m/z calcd for C31H52NO7S [M-Na]− 582.3, found 582.2.
1H NMR (500 MHz, CD3OD) δ 5.03 (d, J=10.6 Hz, 0.4H), 4.43 (d, J=13.0 Hz, 0.6H), 4.33-4.26 (m, 0.6H), 4.00-3.89 (m, 1.4H), 3.57-3.46 (m, 1H), 3.24 (dd, J=13.5, 11.1 Hz, 0.6H), 3.01 (td, J=13.2, 2.7 Hz, 0.4H), 2.83-2.56 (m, 2H), 2.56-2.40 (m, 1H), 2.39-2.21 (m, 2H), 1.96-1.69 (m, 9H), 1.67-1.57 (m, 3H), 1.57-1.24 (m, 12H), 1.23-0.94 (m, 6H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.2.
1H NMR (500 MHz, CD3OD) δ 5.02 (d, J=10.4 Hz, 0.4H), 4.44 (d, J=13.0 Hz, 0.6H), 4.34-4.27 (m, 0.6H), 3.99-3.89 (m, 1.4H), 3.56-3.46 (m, 1H), 3.23 (dd, J=13.6, 11.2 Hz, 0.6H), 3.01 (td, J=13.2, 2.8 Hz, 0.4H), 2.83-2.54 (m, 2H), 2.53-2.24 (m, 3H), 1.95-1.68 (m, 9H), 1.67-1.55 (m, 3H), 1.55-1.23 (m, 12H), 1.23-1.02 (m, 5H), 1.02-0.95 (m, 1H), 0.93 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.2.
1H NMR (400 MHz, DMSO-d6) δ 4.45 (d, J=4.0 Hz, 1H), 4.21 (d, J=4.0 Hz, 1H), 4.16 (td, J=8.4, 3.8 Hz, 1H), 4.05-3.96 (m, 1H), 3.85 (t, J=9.0 Hz, 1H), 3.80-3.71 (m, 2H), 3.44-3.35 (m, 2H), 2.06-1.94 (m, 1H), 1.94-1.40 (m, 11H), 1.40-0.85 (m, 17H), 0.84 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO6S [M-Na]− 510.3, found 510.1.
1H NMR (500 MHz, CD3OD) δ 3.95 (t, J=3.0 Hz, 1H), 3.51 (tt, J=11.1, 4.6 Hz, 1H), 3.20-3.11 (m, 2H), 2.25-2.16 (m, 1H), 2.10-2.00 (m, 1H), 1.95-1.71 (m, 7H), 1.66-1.23 (m, 20H), 1.23-1.05 (m, 2H), 1.03-0.94 (m, 4H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C28H48NO6S [M-Na]− 526.3, found 526.2.
1H NMR (500 MHz, CD3OD) δ 7.29-7.22 (m, 4H), 7.22-7.14 (m, 1H), 4.51-4.43 (m, 1H), 3.94 (t, J=3.0 Hz, 1H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 3.17 (dd, J=13.6, 6.1 Hz, 1H), 3.04-2.94 (m, 2H), 2.91 (dd, J=13.7, 7.9 Hz, 1H), 2.18 (ddd, J=13.8, 10.6, 5.1 Hz, 1H), 2.02 (ddd, J=13.8, 10.3, 6.2 Hz, 1H), 1.95-1.73 (m, 6H), 1.73-1.32 (m, 12H), 1.31-1.03 (m, 5H), 1.03-0.94 (m, 4H), 0.93 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO6S [M-Na]− 588.3, found 588.3.
1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J=7.5 Hz, 1H), 7.29-7.11 (m, 5H), 4.45 (d, J=4.3 Hz, 1H), 4.22-4.06 (m, 2H), 3.78 (s, 1H), 3.41-3.31 (m, 1H), 3.13 (dd, J=13.3, 6.0 Hz, 1H), 2.75 (dd, J=13.3, 6.9 Hz, 1H), 2.54-2.51 (m, 2H), 2.07-1.94 (m, 1H), 1.93-1.41 (m, 11H), 1.38-0.93 (m, 13H), 0.89 (d, J=6.5 Hz, 4H), 0.84 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO6S [M-Na]− 588.3, found 588.3.
1H NMR (500 MHz, CD3OD) δ 4.24-4.17 (m, 1H), 3.96 (t, J=3.0 Hz, 1H), 3.52 (tt, J=11.1, 4.5 Hz, 1H), 2.98-2.92 (m, 2H), 2.30 (ddd, J=13.8, 10.5, 5.1 Hz, 1H), 2.16-2.03 (m, 2H), 1.96-1.73 (m, 7H), 1.67-1.23 (m, 14H), 1.23-1.05 (m, 2H), 1.02 (d, J=6.5 Hz, 3H), 1.01-0.94 (m, 1H), 0.94-0.88 (m, 9H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.2.
1H NMR (400 MHz, DMSO-d6) δ 7.46 (d, J=8.5 Hz, 1H), 4.45 (d, J=4.3 Hz, 1H), 4.19 (d, J=4.0 Hz, 1H), 3.98-3.87 (m, 1H), 3.78 (s, 1H), 3.41-3.28 (m, 1H), 2.54-2.51 (m, 2H), 2.14-1.91 (m, 3H), 1.86-1.40 (m, 10H), 1.40-0.85 (m, 17H), 0.84 (s, 3H), 0.75 (d, J=6.8 Hz, 6H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.2.
1H NMR (500 MHz, CD3OD) δ 7.38-7.33 (m, 2H), 7.33-7.26 (m, 2H), 7.24-7.19 (m, 1H), 5.35 (dd, J=10.0, 3.7 Hz, 1H), 3.97-3.92 (m, 1H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 3.26 (dd, J=14.3, 10.0 Hz, 1H), 3.10 (dd, J=14.3, 3.8 Hz, 1H), 2.32 (ddd, J=13.7, 10.0, 5.0 Hz, 1H), 2.16 (ddd, J=13.9, 9.6, 6.7 Hz, 1H), 1.95-1.73 (m, 7H), 1.65-1.54 (m, 3H), 1.54-1.03 (m, 13H), 1.02-0.94 (m, 4H), 0.93 (s, 3H), 0.67 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO6S [M-Na]− 574.3, found 574.2.
1H NMR (500 MHz, CD3OD) δ 7.37-7.27 (m, 4H), 7.24-7.18 (m, 1H), 5.35 (dd, J=10.0, 3.7 Hz, 1H), 3.97-3.92 (m, 1H), 3.51 (tt, J=11.1, 4.5 Hz, 1H), 3.26 (dd, J=14.3, 10.0 Hz, 1H), 3.09 (dd, J=14.3, 3.7 Hz, 1H), 2.30 (ddd, J=14.0, 9.6, 4.6 Hz, 1H), 2.18 (ddd, J=13.7, 8.7, 7.2 Hz, 1H), 1.95-1.73 (m, 7H), 1.64-1.09 (m, 15H), 1.09-0.94 (m, 5H), 0.93 (s, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO6S [M-Na]− 574.3, found 574.2.
1H NMR (500 MHz, CD3OD) δ 4.52-4.37 (m, 1H), 3.99-3.93 (m, 1H), 3.59-3.32 (m, 3.5H), 3.02-2.90 (m, 1H), 2.73 (dd, J=13.3, 10.6 Hz, 0.5H), 2.60-2.51 (m, 0.5H), 2.47-2.28 (m, 2H), 2.21 (ddd, J=15.1, 10.1, 5.9 Hz, 0.5H), 2.11-1.69 (m, 10H), 1.67-1.23 (m, 14H), 1.23-1.07 (m, 2H), 1.05 (d, J=6.5 Hz, 1.5H), 1.03 (d, J=6.5 Hz, 1.5H), 1.01-0.94 (m, 1H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.2.
1H NMR (500 MHz, CD3OD) δ 4.52-4.38 (m, 1H), 3.99-3.93 (m, 1H), 3.60-3.33 (m, 3.5H), 3.02-2.90 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.50-2.39 (m, 2H), 2.35 (ddd, J=15.3, 10.6, 5.1 Hz, 0.5H), 2.23 (ddd, J=14.6, 10.2, 5.9 Hz, 0.5H), 2.11-1.70 (m, 10H), 1.67-1.23 (m, 14H), 1.23-1.07 (m, 2H), 1.05 (d, J=6.5 Hz, 1.5H), 1.03 (d, J=6.5 Hz, 1.5H), 0.933 (s, 1.5H), 0.931 (s, 1.5H), 1.01-0.95 (m, 1H), 0.933 (s, 1.5H), 0.931 (s, 1.5H), 0.713 (s, 1.5H), 0.711 (s, 1.5H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.2.
1H NMR (400 MHz, DMSO-d6) δ 7.62-7.55 (m, 1H), 4.45 (d, J=4.3 Hz, 1H), 4.19 (d, J=3.9 Hz, 1H), 3.78 (s, 1H), 3.41-3.22 (m, 2H), 3.17-3.06 (m, 1H), 2.48-2.41 (m, 1H), 2.06 (ddd, J=14.5, 9.8, 5.0 Hz, 1H), 2.00-1.88 (m, 1H), 1.86-1.41 (m, 10H), 1.40-0.85 (m, 20H), 0.84 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.2.
1H NMR (500 MHz, CD3OD) δ 3.96 (t, J=3.0 Hz, 1H), 3.59-3.41 (m, 3H), 2.99-2.89 (m, 1H), 2.27 (ddd, J=13.8, 10.1, 5.0 Hz, 1H), 2.12 (ddd, J=13.9, 9.7, 6.6 Hz, 1H), 1.95-1.74 (m, 7H), 1.67-1.55 (m, 3H), 1.55-1.24 (m, 14H), 1.22-1.04 (m, 2H), 1.02 (d, J=6.5 Hz, 3H), 1.01-0.94 (m, 1H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.26 (m, 1H), 3.96 (t, J=3.2 Hz, 1H), 3.76-3.65 (m, 2H), 3.52 (tt, J=11.1, 4.5 Hz, 1H), 3.14-3.07 (m, 1H), 3.06-2.99 (m, 1H), 2.32-2.25 (m, 1H), 2.17-2.09 (m, 1H), 1.95-1.73 (m, 7H), 1.66-1.55 (m, 3H), 1.55-1.23 (m, 11H), 1.23-1.06 (m, 2H), 1.04-0.94 (m, 4H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.2.
1H NMR (400 MHz, DMSO-d6) δ 7.61 (d, J=4.5 Hz, 1H), 4.45 (d, J=4.4 Hz, 1H), 4.20 (d, J=4.0 Hz, 1H), 3.93-3.84 (m, 1H), 3.81-3.75 (m, 1H), 3.41-3.28 (m, 1H), 2.48-2.42 (m, 1H), 2.25-2.13 (m, 1H), 2.08-1.86 (m, 2H), 1.86-1.67 (m, 7H), 1.67-1.41 (m, 6H), 1.41-0.85 (m, 21H), 0.84 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO6S [M-Na]− 552.3, found 552.3.
1H NMR (500 MHz, CD3OD) δ 4.33-4.27 (m, 1H), 3.96 (t, J=3.0 Hz, 1H), 3.51 (tt, J=11.1, 4.6 Hz, 1H), 2.91 (dt, J=10.1, 4.0 Hz, 1H), 2.32 (ddd, J=14.2, 10.2, 5.2 Hz, 1H), 2.25-2.18 (m, 1H), 2.13 (ddd, J=14.3, 9.9, 6.5 Hz, 1H), 2.07-1.74 (m, 10H), 1.67-1.57 (m, 3H), 1.55-1.23 (m, 15H), 1.22-1.05 (m, 2H), 1.02 (d, J=6.5 Hz, 3H), 1.00-0.94 (m, 1H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO6S [M-Na]− 552.3, found 552.3.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.98-3.93 (m, 1H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 3.05 (dd, J=13.9, 5.5 Hz, 1H), 2.87 (dd, J=13.9, 7.0 Hz, 1H), 2.23 (ddd, J=13.8, 10.2, 5.1 Hz, 1H), 2.08 (ddd, J=13.8, 9.7, 6.5 Hz, 1H), 1.95-1.73 (m, 7H), 1.66-1.57 (m, 3H), 1.57-1.23 (m, 14H), 1.22-1.04 (m, 2H), 1.01 (d, J=6.5 Hz, 3H), 1.00-0.94 (m, 1H), 0.93 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.2.
1H NMR (400 MHz, DMSO-d6) δ 7.67 (d, J=7.4 Hz, 1H), 4.45 (d, J=4.3 Hz, 1H), 4.19 (s, 1H), 4.05-3.91 (m, 1H), 3.78 (s, 1H), 3.41-3.28 (m, 1H), 2.60 (dd, J=13.4, 4.6 Hz, 1H), 2.45 (dd, J=13.4, 8.0 Hz, 1H), 2.02 (ddd, J=14.6, 9.9, 5.1 Hz, 1H), 1.94-1.40 (m, 11H), 1.40-0.85 (m, 20H), 0.84 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.2.
1H NMR (500 MHz, CD3OD) δ 4.39-4.31 (m, 1H), 3.96 (t, J=3.0 Hz, 1H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 3.02 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.3 Hz, 1H), 2.25 (ddd, J=13.8, 9.9, 5.1 Hz, 1H), 2.10 (ddd, J=13.7, 9.5, 6.9 Hz, 1H), 1.95-1.74 (m, 7H), 1.73-1.23 (m, 17H), 1.23-1.04 (m, 2H), 1.04-0.95 (m, 4H), 0.95-0.89 (m, 9H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO6S [M-Na]− 554.4, found 554.3.
1H NMR (400 MHz, DMSO-d6) δ 7.54 (d, J=8.6 Hz, 1H), 4.45 (d, J=4.3 Hz, 1H), 4.18 (d, J=3.7 Hz, 1H), 4.12-4.01 (m, 1H), 3.78 (s, 1H), 3.41-3.29 (m, 1H), 2.59 (dd, J=13.5, 4.5 Hz, 1H), 2.46 (dd, J=13.5, 7.5 Hz, 1H), 2.05-1.86 (m, 2H), 1.83-1.41 (m, 12H), 1.40-0.74 (m, 27H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO6S [M-Na]− 554.4, found 554.3.
1H NMR (500 MHz, CD3OD) δ 3.97-3.92 (m, 1H), 3.56-3.46 (m, 1H), 3.03 (s, 2H), 2.21 (ddd, J=13.9, 10.2, 5.0 Hz, 1H), 2.06 (ddd, J=14.0, 9.7, 6.5 Hz, 1H), 1.94-1.70 (m, 7H), 1.66-1.56 (m, 3H), 1.55-1.22 (m, 11H), 1.22-1.04 (m, 2H), 1.02-0.94 (i, 6H), 0.93 (s, 3H), 0.81-0.76 (m, 2H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C28H46NO6S [M-Na]− 524.3, found 524.3.
1H NMR (400 MHz, DMSO-d6) δ 4.45 (d, J=4.3 Hz, 1H), 4.22 (d, J=4.0 Hz, 0.5H), 4.20 (d, J=3.4 Hz, 0.5H), 3.79 (s, 1H), 3.63-3.30 (m, 4.5H), 3.25-3.14 (m, 1H), 3.13-3.04 (m, 0.5H), 2.26-1.87 (m, 4H), 1.86-1.67 (m, 4H), 1.67-1.41 (m, 6H), 1.40-1.12 (m, 11H), 1.12-0.80 (m, 9H), 0.60 (s, 1.5H), 0.59 (s, 1.5H); LCMS (ESI) m/z calcd for C28H46NO6S [M-Na]− 524.3, found 524.2.
1H NMR (500 MHz, CD3OD) 3.98-3.93 (m, 1H), 3.90-3.65 (m, 3H), 3.65-3.40 (m, 3H), 2.47-2.18 (m, 4H), 1.95-1.71 (m, 7H), 1.66-1.56 (m, 3H), 1.56-1.24 (m, 11H), 1.23-1.07 (m, 2H), 1.04 (d, J=6.4 Hz, 1.5H), 1.03 (d, J=6.5 Hz, 1.5H), 1.01-0.94 (m, 1H), 0.93 (s, 3H), 0.72 (s, 1.5H), 0.71 (s, 1.5H); LCMS (ESI) m/z calcd for C28H46NO6S [M-Na]− 524.3, found 524.2.
1H NMR (500 MHz, CD3OD) δ 3.99-3.93 (m, 1H), 3.81-3.75 (m, 1H), 3.74-3.68 (m, 1H), 3.60-3.46 (m, 3H), 3.11-3.02 (m, 2H), 2.59-2.33 (m, 4H), 2.31 (s, 3H), 2.29 (s, 3H), 1.95-1.72 (m, 7H), 1.68-1.56 (m, 3H), 1.55-1.23 (m, 11H), 1.23-1.06 (m, 2H), 1.06-1.02 (m, 3H), 0.98 (td, J=14.2, 3.1 Hz, 1H), 0.93 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C30H53N2O6S [M-Na]− 569.4, found 569.3.
1H NMR (500 MHz, CD3OD) δ8.53-8.41 (m, 2H), 7.80-7.76 (m, 0.7H), 7.76-7.72 (m, 0.3H), 7.49-7.45 (m, 0.3H), 7.43-7.38 (m, 0.7H), 4.84 (s, 1H), 4.69-4.65 (m, 1H), 3.96 (t, J=3.0 Hz, 0.7H), 3.91 (t, J=3.0 Hz, 0.3H), 3.84-3.69 (m, 2H), 3.56-3.46 (m, 1H), 3.11-3.04 (m, 2H), 2.64-2.54 (m, 0.7H), 2.52-2.39 (m, 1H), 2.36-2.27 (m, 0.3H), 1.95-1.69 (m, 7H), 1.67-1.55 (m, 3H), 1.55-1.31 (m, 9H), 1.32-1.03 (m, 6H), 1.02-0.89 (m, 5H), 0.71 (s, 2H), 0.68 (s, 1H); LCMS (ESI) m/z calcd for C32H49N2O6S [M-Na]− 589.3, found 589.3.
1H NMR (500 MHz, CD3OD) δ7.52-7.46 (m, 2H), 7.45-7.38 (m, 1H), 7.35-7.29 (m, 2H), 4.13-4.06 (m, 2H), 3.85 (t, J=3.0 Hz, 1H), 3.50 (tt, J=11.1, 4.6 Hz, 1H), 3.09-3.02 (m, 2H), 2.19-2.09 (m, 1H), 2.03-1.94 (m, 1H), 1.93-1.62 (m, 7H), 1.62-1.34 (m, 10H), 1.32-0.87 (m, 10H), 0.76 (d, J=6.1 Hz, 3H), 0.63 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO6S [M-Na]− 574.3, found 574.3.
1H NMR (500 MHz, CD3OD) δ 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.39 (t, J=7.0 Hz, 2H), 2.34 (t, J=7.0 Hz, 2H), 2.22 (ddd, J=13.8, 10.4, 5.2 Hz, 1H), 2.07 (ddd, J=13.8, 10.1, 6.4 Hz, 1H), 2.01 (dt, J=12.5, 3.2 Hz, 1H), 1.95-1.85 (m, 2H), 1.84-1.71 (m, 3H), 1.66-1.57 (m, 2H), 1.51-1.23 (m, 12H), 1.23-1.03 (m, 5H), 1.03-0.93 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO4 [M-Na]− 446.3, found 446.3.
1H NMR (5 MHz, CD2OD) δ 3.58 (t, J=6.3 Hz, 2H), 3.56-3.50 (m, 1H), 3.25 (td, J=6.9, 1.3 Hz, 2H), 2.23 (ddd, J=13.7, 10.0, 5.2 Hz, 1H), 2.09 (ddd, J=13.8, 9.7, 6.7 Hz, 1H), 2.02 (dt, J=12.3, 3.5 Hz, 1H), 1.96-1.85 (m, 1H), 1.85-1.74 (m, 3H), 1.73-1.67 (m, 2H), 1.66-1.56 (m, 2H), 1.51-1.24 (m, 13H), 1.23-1.05 (m, 5H), 1.03-0.92 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO3 [M-H]− 432.3, found 432.3.
1H NMR (400 MHz, DMSO-d6) δ 4.42 (t, J=5.6 Hz, 1H), 3.57-3.42 (m, 2H), 3.40-3.27 (m, 1H), 2.93 (s, 1.5H), 2.75 (s, 1.5H), 2.70-2.58 (m, 1H), 2.58-2.52 (m, 1H), 2.37-2.06 (m, 2H), 1.97-1.87 (m, 1H), 1.87-1.73 (m, 2H), 1.72-1.44 (m, 5H), 1.42-0.96 (m, 17H), 0.95-0.81 (m, 7H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.2.
1H NMR (500 MHz, CD3OD) δ 7.41-7.34 (m, 1H), 7.34-7.20 (m, 4H), 4.79-4.69 (m, 1H), 4.68-4.58 (m, 1H), 3.84-3.68 (m, 2H), 3.57-3.48 (m, 1H), 3.07 (t, J=7.1 Hz, 1H), 3.05-2.97 (m, 1H), 2.57 (ddd, J=15.2, 10.3, 5.2 Hz, 0.5H), 2.50-2.33 (m, 1H), 2.27 (ddd, J=15.4, 10.4, 5.7 Hz, 0.5H), 2.06-1.68 (m, 6H), 1.66-0.85 (m, 26H), 0.70 (s, 1.5H), 0.65 (s, 1.5H); LCMS (ESI) m/z calcd for C33H50NO5S [M-Na]− 572.3, found 572.3.
1H NMR (500 MHz, CD3OD) δ3.89-3.78 (m, 1H), 3.77-3.69 (m, 2H), 3.67 (t, J=5.7 Hz, 1H), 3.58-3.44 (m, 3H), 3.13-3.04 (m, 2H), 2.55-2.44 (m, 1H), 2.41-2.29 (m, 1H), 2.05-1.99 (m, 1H), 1.98-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.60 (s, 2H), 1.52-1.04 (m, 17H), 1.02-0.94 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C28H48NO6S [M-Na]− 526.3, found 526.3.
1H NMR (500 MHz, CD3OD) δ 4.66-4.55 (m, 0.5H), 4.21-4.12 (m, 0.5H), 3.72-3.65 (m, 1H), 3.65-3.58 (m, 1H), 3.58-3.47 (m, 1H), 3.10-3.01 (m, 2H), 2.44 (ddd, J=15.3, 10.5, 5.1 Hz, 1H), 2.37-2.25 (m, 1H), 2.05-1.99 (m, 1H), 1.95-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.66-1.57 (m, 2H), 1.51-1.04 (m, 23H), 1.03-0.93 (m, 7H), 0.70 (s, 1.5H), 0.69 (s, 1.5H); LCMS (ESI) m/z calcd for C29H50NO5S [M-Na]− 524.3, found 524.3.
1H NMR (500 MHz, CD3OD) δ4.43 (tt, J=12.1, 3.9 Hz, 0.5H), 4.06-3.89 (m, 2.5H), 3.75-3.62 (m, 2H), 3.58-3.42 (m, 3H), 3.08-3.01 (m, 2H), 2.53-2.42 (m, 1H), 2.40-2.30 (m, 1H), 2.05-1.85 (m, 5H), 1.85-1.70 (m, 3H), 1.70-1.54 (m, 4H), 1.50-1.04 (m, 17H), 1.03-0.95 (m, 4H), 0.949 (s, 1.5H), 0.945 (s, 1.5H), 0.70 (s, 1.5H), 0.69 (s, 1.5H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.3.
1H NMR (500 MHz, CD3OD) δ 5.05-4.98 (m, 0.4H), 4.42 (d, J=12.9 Hz, 0.6H), 4.32-4.25 (m, 0.6H), 3.92 (d, J=12.9 Hz, 0.4H), 3.52 (tt, J=11.4, 4.3 Hz, 1H), 3.24 (dd, J=13.5, 11.1 Hz, 0.6H), 3.01 (td, J=13.2, 2.8 Hz, 0.4H), 2.84-2.56 (m, 2H), 2.56-2.39 (m, 1H), 2.38-2.24 (m, 2H), 2.02 (dt, J=12.4, 3.1 Hz, 1H), 1.98-1.68 (m, 7H), 1.66-1.57 (m, 2H), 1.54-1.05 (m, 18H), 1.03-0.97 (m, 4H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (400 MHz, DMSO-d6) δ4.71 (d, J=13.6 Hz, 0.5H), 4.42 (s, 1H), 4.28 (d, J=12.9 Hz, 0.5H), 4.03 (d, J=13.2 Hz, 0.5H), 3.77 (d, J=13.3 Hz, 0.5H), 3.41-3.27 (m, 1H), 2.99-2.88 (m, 0.5H), 2.85-2.75 (m, 0.5H), 2.42-2.24 (m, 2.5H), 2.22-2.08 (m, 1.5H), 2.06-1.98 (m, 1H), 1.96-1.89 (m, 1H), 1.83-1.73 (m, 2H), 1.72-1.43 (m, 7H), 1.43-0.96 (m, 18H), 0.94-0.84 (m, 7H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (400 MHz, DMSO-d6) δ 4.45-4.32 (m, 2H), 3.85 (d, J=13.5 Hz, 1H), 3.41-3.27 (m, 1H), 2.92 (t, J=12.5 Hz, 1H), 2.47-2.37 (m, 2H), 2.36-2.10 (m, 2H), 1.96-1.72 (m, 5H), 1.72-1.44 (m, 5H), 1.44-0.96 (m, 19H), 0.95-0.82 (m, 7H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C29H48N5S [M-Na]− 522.3, found 522.2.
1H NMR (500 MHz, CD3OD) δ 4.42 (t, J=8.8 Hz, 1H), 4.36-4.30 (m, 1H), 4.21-4.11 (m, 2H), 3.85-3.76 (m, 1H), 3.58-3.48 (m, 1H), 2.25-2.12 (m, 1H), 2.11-1.98 (m, 2H), 1.95-1.85 (m, 2H), 1.85-1.69 (m, 3H), 1.65-1.57 (m, 2H), 1.51-1.05 (m, 17H), 1.03-0.98 (m, 1H), 0.96 (d, J=6.5 Hz, 3H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (500 MHz, CD3OD) 3.57-3.48 (m, 1H), 3.21-3.09 (m, 2H), 2.19 (ddd, J=13.9, 10.3, 5.2 Hz, 1H), 2.08-1.98 (m, 2H), 1.96-1.85 (m, 2H), 1.84-1.71 (m, 3H), 1.67-1.56 (m, 2H), 1.53 (s, 6H), 1.50-1.04 (m, 17H), 1.03-0.92 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C28H48NO5S [M-Na]− 510.3, found 510.3.
1H NMR (500 MHz, CD3OD) δ7.29-7.22 (m, 4H), 7.22-7.14 (m, 1H), 4.50-4.42 (m, 1H), 3.58-3.48 (m, 1H), 3.20-3.13 (m, 1H), 3.05-2.95 (m, 2H), 2.92 (dd, J=13.6, 7.8 Hz, 1H), 2.16 (ddd, J=13.8, 10.8, 5.1 Hz, 1H), 2.00 (ddd, J=13.8, 10.5, 6.2 Hz, 2H), 1.96-1.57 (m, 7H), 1.50-1.04 (m, 17H), 1.03-0.95 (m, 1H), 0.94 (s, 3H), 0.92 (d, J=6.6 Hz, 3H), 0.67 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO5S [M-Na]− 572.3, found 572.3.
1H NMR (500 MHz, CD3OD) δ 7.30-7.22 (m, 4H), 7.22-7.14 (m, 1H), 4.52-4.43 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.16 (dd, J=13.7, 6.1 Hz, 1H), 3.04-2.93 (m, 2H), 2.91 (dd, J=13.7, 7.8 Hz, 1H), 2.17 (ddd, J=13.8, 10.4, 5.1 Hz, 1H), 2.06-1.96 (m, 2H), 1.96-1.55 (m, 7H), 1.51-1.04 (m, 17H), 0.99 (td, J=14.1, 3.3 Hz, 1H), 0.94 (s, 3H), 0.91 (d, J=6.5 Hz, 3H), 0.66 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO5S [M-Na]− 572.3, found 572.3.
1H NMR (500 MHz, CD3OD) δ 4.23-4.16 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.01-2.90 (m, 2H), 2.28 (ddd, J=13.7, 10.6, 5.2 Hz, 1H), 2.15-1.98 (m, 3H), 1.97-1.86 (m, 2H), 1.85-1.71 (m, 3H), 1.65-1.56 (m, 2H), 1.51-1.23 (m, 12H), 1.23-1.03 (m, 5H), 1.03-0.88 (m, 13H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO5S [M-Na]− 524.3, found 524.3.
1H NMR (400 MHz, DMSO-d6) δ 7.46 (d, J=8.4 Hz, 1H), 4.42 (d, J=4.6 Hz, 1H), 3.98-3.87 (m, 1H), 3.41-3.27 (m, 1H), 2.55-2.51 (m, 2H), 2.15-1.88 (m, 4H), 1.84-1.72 (m, 2H), 1.72-1.43 (m, 5H), 1.41-0.95 (m, 17H), 0.94-0.82 (m, 7H), 0.76 (s, 3H), 0.74 (s, 3H), 0.60 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO5S [M-Na]− 524.3, found 524.3.
1H NMR (500 MHz, CD3OD) 7.37-7.27 (m, 4H), 7.24-7.19 (m, 1H), 5.35 (dd, J=10.0, 3.7 Hz, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.26 (dd, J=14.3, 10.0 Hz, 1H), 3.09 (dd, J=14.3, 3.8 Hz, 1H), 2.31 (ddd, J=13.9, 10.1, 5.4 Hz, 1H), 2.15 (ddd, J=14.0, 9.8, 6.5 Hz, 1H), 1.99 (dt, J=12.5, 3.3 Hz, 1H), 1.95-1.71 (m, 5H), 1.66-1.52 (m, 2H), 1.52-1.21 (m, 12H), 1.21-0.90 (m, 12H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO5S [M-Na]− 558.3, found 558.3.
1H NMR (500 MHz, CD3OD) δ 7.37-7.26 (m, 4H), 7.24-7.18 (m, 1H), 5.35 (dd, J=10.1, 3.7 Hz, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.26 (dd, J=14.3, 10.1 Hz, 1H), 3.09 (dd, J=14.3, 3.7 Hz, 1H), 2.29 (ddd, J=14.4, 9.7, 5.0 Hz, 1H), 2.17 (ddd, J=13.9, 9.2, 7.1 Hz, 1H), 2.00 (dt, J=12.4, 3.2 Hz, 1H), 1.95-1.71 (m, 5H), 1.65-1.52 (m, 2H), 1.51-0.91 (m, 24H), 0.63 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO5S [M-Na]− 558.3, found 558.3.
1H NMR (500 MHz, CD3OD) δ 4.52-4.44 (m, 0.5H), 4.44-4.37 (m, 0.5H), 3.59-3.32 (m, 3.5H), 3.02-2.90 (m, 1H), 2.73 (dd, J=13.3, 10.6 Hz, 0.5H), 2.55 (ddd, J=15.3, 10.6, 5.3 Hz, 0.5H), 2.47-2.27 (m, 2H), 2.19 (ddd, J=14.7, 10.4, 5.8 Hz, 0.5H), 2.11-1.85 (m, 6H), 1.85-1.70 (m, 3H), 1.66-1.56 (m, 2H), 1.50-1.03 (m, 17H), 1.02-0.91 (m, 4H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (500 MHz, CD3OD) δ 4.51-4.44 (m, 0.5H), 4.44-4.37 (m, 0.5H), 3.59-3.32 (m, 3.5H), 3.01-2.90 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.48-2.38 (m, 2H), 2.34 (ddd, J=15.5, 10.8, 5.2 Hz, 0.5H), 2.21 (ddd, J=14.7, 10.5, 5.8 Hz, 0.5H), 2.10-1.85 (m, 6H), 1.85-1.71 (m, 3H), 1.67-1.56 (m, 2H), 1.50-1.03 (m, 17H), 1.03-0.96 (m, 4H), 0.95 (s, 3H), 0.694 (s, 1.5H), 0.690 (s, 1.5H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (500 MHz, CD3OD) δ 3.61-3.48 (m, 2H), 3.44 (dd, J=13.8, 6.7 Hz, 1H), 3.00-2.90 (m, 1H), 2.25 (ddd, J=13.9, 10.2, 5.1 Hz, 1H), 2.11 (ddd, J=13.9, 9.8, 6.7 Hz, 1H), 2.01 (dt, J=12.4, 3.2 Hz, 1H), 1.96-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.66-1.57 (m, 2H), 1.51-1.24 (m, 15H), 1.23-1.03 (m, 5H), 1.03-0.98 (m, 1H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.2.
1H NMR (500 MHz, CD3OD) δ 3.59-3.49 (m, 2H), 3.46 (dd, J=13.7, 6.8 Hz, 1H), 2.99-2.89 (m, 1H), 2.26 (ddd, J=13.9, 10.3, 5.2 Hz, 1H), 2.11 (ddd, J=14.0, 9.9, 6.6 Hz, 1H), 2.01 (dt, J=12.4, 3.2 Hz, 1H), 1.96-1.85 (m, 2H), 1.84-1.71 (m, 3H), 1.66-1.56 (m, 2H), 1.51-1.23 (m, 15H), 1.23-1.04 (m, 5H), 1.03-0.98 (m, 1H), 0.96 (d, J=0.65 Hz, 3H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.25 (m, 1H), 3.75-3.65 (m, 2H), 3.53 (tt, J=10.5, 4.6 Hz, 1H), 3.13-3.07 (m, 1H), 3.06-3.00 (m, 1H), 2.32-2.17 (m, 1H), 2.16-1.98 (m, 2H), 1.97-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.67-1.55 (m, 2H), 1.51-1.23 (m, 12H), 1.23-1.04 (m, 5H), 1.03-0.90 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.2.
1H NMR (500 MHz, CD3OD) δ 4.33-4.26 (m, 1H), 3.76-3.64 (m, 2H), 3.57-3.48 (m, 1H), 3.14-3.07 (m, 1H), 3.07-2.99 (m, 1H), 2.32-2.17 (m, 1H), 2.16-1.98 (m, 2H), 1.96-1.85 (m, 2H), 1.85-1.72 (m, 3H), 1.66-1.55 (m, 2H), 1.51-1.23 (m, 12H), 1.23-1.04 (m, 5H), 1.03-0.91 (m, 7H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO6S [M-Na]− 512.3, found 512.3.
1H NMR (500 MHz, CD3OD) δ 4.33-4.27 (m, 1H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 2.91 (dt, J=10.2, 4.0 Hz, 1H), 2.31-2.19 (m, 2H), 2.15 (ddd, J=14.1, 9.6, 6.9 Hz, 1H), 2.07-1.85 (m, 6H), 1.84-1.71 (m, 3H), 1.66-1.56 (m, 2H), 1.55-1.24 (m, 16H), 1.23-1.03 (m, 5H), 1.02-0.98 (m, 1H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (s, 3H), 0.68 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO5S [M-Na]− 536.3, found 536.3.
1H NMR (500 MHz, CD3OD) δ 4.33-4.27 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 2.91 (dt, J=10.1, 4.0 Hz, 1H), 2.31 (ddd, J=14.2, 10.3, 5.3 Hz, 1H), 2.25-2.18 (m, 1H), 2.12 (ddd, J=14.3, 10.1, 6.4 Hz, 1H), 2.06-1.85 (m, 6H), 1.84-1.72 (m, 3H), 1.66-1.56 (m, 2H), 1.55-1.24 (m, 16H), 1.24-1.03 (m, 5H), 1.03-0.98 (m, 1H), 0.96 (d, J=6.5 Hz, 3H), 0.95 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO5S [M-Na]− 536.3, found 536.3.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.58-3.48 (m, 1H), 3.05 (dd, J=13.9, 5.5 Hz, 1H), 2.88 (dd, J=13.9, 7.0 Hz, 1H), 2.22 (ddd, J=13.8, 10.3, 5.2 Hz, 1H), 2.12-1.98 (m, 2H), 1.96-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.66-1.56 (m, 2H), 1.51-1.24 (m, 15H), 1.23-1.03 (m, 5H), 1.03-0.97 (m, 1H), 0.96 (d, J=6.5 Hz, 3H), 0.94 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.2.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.05 (dd, J=13.9, 5.6 Hz, 1H), 2.88 (dd, J=13.9, 6.9 Hz, 1H), 2.22 (ddd, J=13.8, 10.2, 5.1 Hz, 1H), 2.11-1.98 (m, 2H), 1.96-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.66-1.56 (m, 2H), 1.50-1.24 (m, 15H), 1.23-1.04 (m, 5H), 1.03-0.97 (m, 1H), 0.96 (d, J=6.5 Hz, 3H), 0.94 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5S [M-Na]− 496.3, found 496.2.
1H NMR (500 MHz, CD3OD) δ 4.39-4.30 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.03 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.2 Hz, 1H), 2.23 (ddd, J=13.8, 9.9, 5.3 Hz, 1H), 2.08 (ddd, J=13.8, 9.6, 6.8 Hz, 1H), 2.02 (dt, J=12.4, 3.2 Hz, 1H), 1.96-1.85 (m, 2H), 1.85-1.72 (m, 3H), 1.70-1.52 (m, 5H), 1.51-1.24 (m, 12H), 1.23-1.04 (m, 5H), 1.04-0.89 (m, 13H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO5S [M-Na]− 538.4, found 538.3.
1H NMR (500 MHz, CD3OD) δ 4.42-4.33 (m, 1H), 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.01 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.3 Hz, 1H), 2.22 (ddd, J=14.2, 9.4, 5.1 Hz, 1H), 2.10 (ddd, J=13.8, 9.0, 7.4 Hz, 1H), 2.01 (dt, J=12.5, 3.2 Hz, 1H), 1.96-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.71-1.51 (m, 5H), 1.50-1.04 (m, 17H), 1.04-0.89 (m, 13H), 0.68 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO5S [M-Na]− 538.4, found 538.3.
1H NMR (500 MHz, CD3OD) δ 3.53 (tt, J=11.1, 4.6 Hz, 1H), 3.08-2.97 (m, 2H), 2.20 (ddd, J=14.0, 10.4, 5.2 Hz, 1H), 2.09-1.97 (m, 2H), 1.96-1.85 (m, 2H), 1.85-1.70 (m, 3H), 1.66-1.56 (m, 2H), 1.51-1.23 (m, 12H), 1.22-1.04 (m, 5H), 1.03-0.90 (m, 9H), 0.82-0.76 (m, 2H), 0.68 (s, 3H); LCMS (ESI) m/z calcd for C28H46NO5S [M-Na]− 508.3, found 508.3.
1H NMR (500 MHz, CD3OD) δ3.88-3.65 (m, 3H), 3.65-3.39 (m, 3H), 2.47-2.16 (m, 4H), 2.09-1.99 (m, 1H), 1.95-1.85 (m, 2H), 1.85-1.71 (m, 3H), 1.67-1.56 (m, 2H), 1.53-1.04 (m, 17H), 1.04-0.92 (m, 7H), 0.73-0.65 (m, 3H); LCMS (ESI) m/z calcd for C28H46NO5S [M-Na]− 508.3, found 508.3.
1H NMR (400 MHz, DMSO-d6) δ 4.43 (s, 1H), 3.65-3.29 (m, 4.5H), 3.27-3.14 (m, 1H), 3.13-3.04 (m, 0.5H), 2.26-2.14 (m, 1H), 2.14-1.87 (m, 4H), 1.85-1.73 (m, 2H), 1.72-1.44 (m, 5H), 1.43-0.96 (m, 17H), 0.94-0.81 (m, 7H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C28H46NO5S [M-Na]− 508.3, found 508.3.
1H NMR (500 MHz, CD3OD) δ3.80-3.74 (m, 1H), 3.73-3.68 (m, 1H), 3.59-3.44 (m, 3H), 3.12-3.02 (m, 2H), 2.58-2.22 (m, 10H), 2.02 (dt, J=12.5, 3.1 Hz, 1H), 1.96-1.85 (m, 2H), 1.84-1.71 (m, 3H), 1.66-1.57 (m, 2H), 1.52-1.05 (m, 17H), 1.03-0.96 (m, 4H), 0.95 (s, 3H), 0.70 (s, 1.5H), 0.69 (s, 1.5H); LCMS (ESI) m/z calcd for C30H53N2O5S [M-Na]− 553.4, found 553.3.
1H NMR (500 MHz, CD3OD) δ 8.52-8.41 (m, 2H), 7.81-7.72 (m, 1H), 7.51-7.37 (m, 1H), 4.86-4.79 (m, 0.6H), 4.72-4.65 (m, 1.4H), 3.84-3.68 (m, 2H), 3.57-3.48 (m, 1H), 3.11-3.02 (m, 2H), 2.63-2.53 (m, 0.3H), 2.34-2.25 (m, 1H), 2.51-2.37 (m, 0.7H), 2.05-1.69 (m, 6H), 1.66-1.54 (m, 2H), 1.52-1.03 (m, 17H), 1.02-0.96 (m, 3H), 0.96-0.92 (m, 3H), 0.86 (d, J=6.5 Hz, 1H), 0.69 (s, 2H), 0.65 (s, 1H); LCMS (ESI) m/z calcd for C32H49N2O5S [M-Na]− 573.3, found 573.3.
1H NMR (500 MHz, CD3OD) δ7.53-7.47 (m, 2H), 7.46-7.39 (m, 1H), 7.35-7.29 (m, 2H), 4.13-4.06 (m, 2H), 3.52 (tt, J=11.1, 4.6 Hz, 1H), 3.09-3.02 (m, 2H), 2.17-2.08 (m, 1H), 2.01-1.83 (m, 3H), 1.83-1.51 (m, 6H), 1.51-0.94 (m, 18H), 0.92 (s, 3H), 0.69 (d, J=6.0 Hz, 3H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO5S [M-Na]− 558.3, found 558.3.
1H NMR (400 MHz, DMSO-d6) δ 7.83 (t, J=5.6 Hz, 1H), 4.31 (s, 1H), 4.09 (s, 1H), 4.01 (s, 1H), 3.78 (s, 1H), 3.61 (s, 1H), 3.24-3.13 (m, 3H), 2.32 (t, J=6.9 Hz, 2H), 2.28-1.87 (m, 5H), 1.83-1.55 (m, 6H), 1.51-1.06 (m, 11H), 1.02-0.82 (m, 5H), 0.81 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO6 [M-Na]− 478.3, found 478.2.
1H NMR (500 MHz, CD3OD) δ3.98-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.58 (t, J=6.4 Hz, 2H), 3.41-3.33 (m, 1H), 3.25 (t, J=7.3 Hz, 2H), 2.33-2.20 (m, 3H), 2.11 (ddd, J=13.7, 9.5, 6.7 Hz, 1H), 2.04-1.49 (m, 15H), 1.48-1.24 (m, 5H), 1.12 (qd, J=12.0, 5.8 Hz, 1H), 1.03 (d, J=6.4 Hz, 3H), 1.02-0.94 (m, 1H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO5 [M-H]− 464.3, found 464.1.
1H NMR (400 MHz, DMSO-d6) δ4.30 (s, 1H), 4.12 (s, 1H), 4.01 (s, 1H), 3.79 (s, 1H), 3.61 (s, 1H), 3.56-3.42 (m, 2H), 3.17 (s, 1H), 2.93 (s, 1.5H) 2.75 (s, 1.5H), 2.69-2.60 (m, 1H), 2.58-2.52 (m, 1H), 2.36-2.07 (m, 4H), 2.05-1.94 (m, 1H), 1.85-1.55 (m, 6H), 1.51-1.07 (m, 11H), 1.03-0.82 (m, 5H), 0.81 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.1.
1H NMR (500 MHz, CD3OD) δ 7.41-7.34 (m, 1H), 7.34-7.20 (m, 4H), 4.74 (s, 1H), 4.63 (s, 1H), 3.99-3.94 (m, 0.5H) 3.92-3.88 (m, 0.5H), 3.82-3.68 (m, 3H), 3.37 (m, 1H), 3.10-2.96 (m, 2H), 2.63-2.54 (m, 0.5H) 2.52-2.39 (m, 1H), 2.36-2.19 (m, 2.5H), 2.06-1.18 (m, 18H), 1.17-0.88 (m, 8H), 0.72 (s, 1.5H), 0.68 (s, 1.5H); LCMS (ESI) m/z calcd for C33H50NO7S [M-Na]− 604.3, found 604.2.
1H NMR (500 MHz, CD3OD) δ 3.99-3.93 (m, 1H), 3.89-3.82 (m, 1H), 3.82-3.77 (m, 1H), 3.77-3.64 (m, 3H), 3.60-3.52 (m, 1H), 3.51-3.44 (m, 1H), 3.41-3.32 (m, 1H), 3.15-3.04 (m, 2H), 2.55-2.47 (m, 1H), 2.41-2.33 (m, 1H), 2.32-2.23 (m, 2H), 2.04-1.70 (m, 7H), 1.69-1.49 (m, 6H), 1.49-1.27 (m, 5H), 1.17-1.02 (m, 4H), 0.98 (td, J=14.2, 3.5 Hz, 1H), 0.92 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C28H48NO8S [M-Na]− 558.3, found 558.2.
1H NMR (400 MHz, DMSO-d6) δ4.55-4.42 (m, 0.6H), 4.31 (s, 1H), 4.11 (s, 1H), 4.15-3.96 (m, 1.4H), 3.79 (s, 1H), 3.61 (s, 1H), 3.45-3.37 (m, 1H), 3.36-3.27 (m, 1H), 3.17 (s, 1H), 2.67-2.54 (m, 2H), 2.34-2.09 (m, 4H), 2.02-1.94 (m, 1H), 1.85-1.55 (m, 6H), 1.51-1.07 (m, 14H), 1.03 (d, J=6.8, 3H), 0.97-0.94 (m, 1H), 0.93 (d, J=6.4, 3H), 0.87-0.83 (m, 1H), 0.81 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (500 MHz, CD3OD) δ 4.44 (tt, J=12.1, 3.9 Hz, 0.5H) 4.06-3.91 (m, 3.5H), 3.83-3.77 (m, 1H), 3.75-3.63 (m, 2H), 3.53-3.41 (m, 2H), 3.41-3.32 (m, 1H), 3.08-3.01 (m, 2H), 2.55-2.44 (m, 1H), 2.41-2.21 (m, 3H), 2.06-1.24 (m, 22H), 1.18-1.08 (m, 1H), 1.07-1.05 (m, 3H), 0.98 (tt, J=14.2, 3.5 Hz, 1H), 0.922 (s, 1.5H), 0.919 (s, 1.5H), 0.73 (s, 1.5H), 0.72 (s, 1.5H); LCMS (ESI) m/z calcd for C31H52NO8S [M-Na]− 598.3, found 598.2.
1H NMR (400 MHz, DMSO-d6) δ4.72 (d, J=12.7 Hz, 0.5H), 4.37-4.22 (m, 1.5H), 4.16-4.07 (m, 1H), 4.07-3.95 (m, 1.5H), 3.84-3.70 (m, 1.5H), 3.61 (s, 1H), 3.24-3.11 (m, 1H), 2.99-2.89 (m, 0.5H), 2.86-2.76 (m, 0.5H), 2.42-2.09 (m, 6H), 2.08-1.91 (m, 2H), 1.86-1.07 (m, 20H), 1.01-0.82 (m, 5H), 0.81 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.2.
1H NMR (500 MHz, CD3OD) δ 5.02 (d, J=9.7 Hz, 0.5H), 4.44 (d, J=13.3 Hz, 0.5H), 4.34-4.27 (m, 0.5H), 3.98-3.94 (m, 1.5H), 3.82-3.77 (m, 1H), 3.41-3.33 (m, 1H), 3.23 (dd, J=13.6, 11.2 Hz, 0.5H), 3.01 (td, J=13.2, 2.8 Hz, 0.5H), 2.84-2.55 (m, 2H), 2.54-2.42 (m, 1H), 2.42-2.21 (m, 4H), 2.07-1.69 (m, 9H), 1.69-1.25 (m, 12H), 1.17-1.08 (m, 1H), 1.06 (d, J=6.5, 1.5H), 1.04 (d, J=6.4, 1.5H), 1.02-0.94 (m, 1H), 0.92 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.2.
1H NMR (400 MHz, D2O) δ 4.50 (d, J=13.5 Hz, 1H), 4.15-4.02 (m, 2H), 3.92-3.85 (m, 1H), 3.55-3.44 (m, 1H), 3.20 (t, J=13.1 Hz, 1H), 3.14-3.03 (m, 1H), 2.78-2.67 (m, 1H), 2.59-2.29 (m, 2H), 2.23-1.22 (m, 24H), 1.22-1.09 (m, 1H), 1.08-0.95 (m, 4H), 0.91 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.2.
1H NMR (500 MHz, CD3OD) δ 4.47-4.38 (m, 1H), 4.38-4.31 (m, 1H), 4.21-4.11 (m, 2H), 3.98-3.93 (m, 1H), 3.85-3.76 (m, 2H), 3.41-3.32 (m, 1H), 2.35-2.14 (m, 3H), 2.13-1.69 (m, 8H), 1.69-1.49 (m, 6H), 1.49-1.27 (m, 5H), 1.12 (qd, J=11.8, 5.3 Hz, 1H), 1.05-0.94 (m, 4H), 0.92 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO7S [M-Na]− 526.3, found 526.1.
1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H), 4.31 (d, J=4.5 Hz, 1H), 4.11 (d, J=3.4 Hz, 1H), 4.01 (d, J=3.4 Hz, 1H), 3.78 (s, 1H), 3.61 (s, 1H), 3.23-3.11 (m, 1H), 2.61 (s, 2H), 2.29-2.08 (m, 2H), 2.04-1.91 (m, 2H), 1.90-1.52 (m, 7H), 1.50-1.07 (m, 17H), 1.02-0.82 (m, 5H), 0.81 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C28H48NO7S [M-Na]− 542.3, found 542.2.
1H NMR (500 MHz, CD3OD) δ 7.30-7.21 (m, 4H), 7.20-7.14 (m, 1H), 4.51-4.42 (m, 1H), 3.95-3.94 (m, 1H), 3.82-3.78 (m, 1H), 3.42-3.34 (m, 1H), 3.21-3.13 (m, 1H), 3.03-2.96 (m, 2H), 2.91 (dd, J=13.6, 7.8 Hz, 1H), 2.34-2.13 (m, 3H), 2.07-1.92 (m, 3H), 1.92-1.49 (m, 11H), 1.48-1.33 (m, 3H), 1.32-1.18 (m, 2H), 1.16-0.93 (m, 5H), 0.92 (s, 3H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO7S [M-Na]− 604.3, found 604.2.
1H NMR (500 MHz, CD3OD) δ 7.30-7.22 (m, 4H), 7.22-7.14 (m, 1H), 4.52-4.44 (m, 1H), 3.96-3.91 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.32 (m, 1H), 3.17 (dd, J=13.6, 6.1 Hz, 1H), 3.03-2.95 (m, 2H), 2.91 (dd, J=13.7, 7.8 Hz, 1H), 2.34-2.15 (m, 3H), 2.08-1.49 (m, 14H), 1.48-1.19 (m, 5H), 1.16-1.04 (m, 1H), 1.03-0.93 (m, 4H), 0.92 (s, 3H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C33H50NO7S [M-Na]− 604.3, found 604.2.
1H NMR (500 MHz, CD3OD) δ 4.24-4.17 (m, 1H), 3.98-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.33 (m, 1H), 2.99-2.92 (m, 2H), 2.35-2.21 (m, 3H), 2.17-2.04 (m, 2H), 2.03-1.69 (m, 7H), 1.69-1.49 (m, 6H), 1.49-1.27 (m, 5H), 1.17-1.06 (m, 1H), 1.03 (d, J=6.5 Hz, 3H), 1.02-0.94 (m, 1H), 0.94-0.89 (m, 9H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (500 MHz, CD3OD) δ 4.23-4.21 (m, 1H), 3.98-3.92 (m, 1H), 3.83-3.75 (m, 1H), 3.41-3.32 (m, 1H), 2.95 (d, J=6.1 Hz, 2H), 2.34-2.21 (m, 3H), 2.21-2.12 (m, 1H), 2.12-2.03 (m, 1H), 2.03-1.69 (m, 7H), 1.69-1.49 (m, 6H), 1.49-1.25 (m, 5H), 1.16-1.07 (m, 1H), 1.04 (d, J=6.4 Hz, 3H), 1.02-0.94 (m, 1H), 0.94-0.89 (m, 9H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (400 MHz, DMSO-d6) δ 8.14 (d, J=6.2 Hz, 1H), 7.29-7.19 (m, 4H), 7.18-7.11 (m, 1H), 5.01-4.92 (m, 1H), 4.31 (d, J=4.5 Hz, 1H), 4.11 (s, 1H), 4.01 (s, 1H), 3.78 (s, 1H), 3.61 (s, 1H), 3.23-3.11 (m, 1H), 2.85 (dd, J=13.8, 9.2 Hz, 1H), 2.66 (dd, J=13.8, 4.2 Hz, 1H), 2.29-2.06 (m, 3H), 2.04-1.89 (m, 2H), 1.85-1.55 (m, 6H), 1.50-1.08 (m, 11H), 0.99-0.82 (m, 5H), 0.81 (s, 3H), 0.57 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO7S [M-Na]− 590.3, found 590.3.
1H NMR (500 MHz, CD3OD) δ7.37-7.27 (m, 4H), 7.24-7.18 (m, 1H), 5.35 (dd, J=10.0, 3.7 Hz, 1H), 3.96-3.91 (m, 1H), 3.81-3.75 (m, 1H), 3.41-3.32 (m, 1H), 3.26 (dd, J=14.3, 10.0 Hz, 1H), 3.10 (dd, J=14.3, 3.7 Hz, 1H), 2.36-2.14 (m, 4H), 2.02-1.48 (m, 13H), 1.48-1.27 (m, 4H), 1.26-1.17 (m, 1H), 1.11-0.94 (m, 5H), 0.92 (s, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO7S [M-Na]− 590.3, found 590.3.
1H NMR (400 MHz, DMSO-d6) δ4.31 (s, 1H), 4.23-4.07 (m, 2H), 4.01 (s, 1H), 3.79 (s, 1H), 3.61 (s, 1H), 3.44-3.27 (m, 1H), 3.26-3.11 (m, 2H), 2.92 (dd, J=12.7, 2.9 Hz, 0.5H), 2.61-2.52 (m, 0.5H), 2.44-1.91 (m, 7H), 1.91-1.54 (m, 9H), 1.51-1.06 (m, 11H), 1.03-0.82 (m, 5H), 0.81 (s, 3H), 0.59 (s, 1.5H), 0.58 (s, 1.5H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.4.
1H NMR (500 MHz, CD3OD) δ 4.52-4.38 (m, 1H), 3.99-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.60-3.52 (m, 0.5H), 3.52-3.26 (m, 3H), 3.02-2.92 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.50-2.40 (m, 2H), 2.39-2.19 (m, 3H), 2.11-1.70 (m, 10H), 1.68-1.49 (m, 6H), 1.49-1.25 (m, 5H), 1.17-1.08 (m, 1H), 1.06 (d, J=6.5 Hz, 1.5H), 1.04 (d, J=6.5 Hz, 1.5H), 1.02-0.94 (m, 1H), 0.92 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.3.
1H NMR (500 MHz, CD3OD) δ 3.99-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.58 (dd, J=13.8, 6.0 Hz, 1H), 3.43 (dd, J=13.8, 6.8 Hz, 1H), 3.40-3.32 (m, 1H), 3.00-2.90 (m, 1H), 2.34-2.21 (m, 3H), 2.13 (ddd, J=13.9, 9.5, 6.8 Hz, 1H), 2.04-1.70 (m, 7H), 1.69-1.49 (m, 6H), 1.47-1.31 (m, 5H), 1.29 (d, J=6.9 Hz, 3H), 1.17-1.06 (m, 1H), 1.03 (d, J=6.4 Hz, 3H), 1.01-0.94 (m, 1H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.2.
1H NMR (400 MHz, DMSO-d6) δ 7.63-7.55 (m, 1H), 4.32 (d, J=4.4 Hz, 1H), 4.10 (d, J=3.3 Hz, 1H), 4.01 (d, J=3.3 Hz, 1H), 3.78 (s, 1H), 3.61 (s, 1H), 3.30-3.09 (m, 3H), 2.49-2.42 (m, 1H), 2.28-1.87 (m, 5H), 1.84-1.52 (m, 6H), 1.50-1.08 (m, 11H), 1.02 (d, J=6.8 Hz, 3H), 0.99-0.82 (m, 5H), 0.80 (s, 3H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.27 (m, 1H), 3.99-3.92 (m, 1H), 3.84-3.77 (m, 1H), 3.75-3.64 (m, 2H), 3.42-3.32 (m, 1H), 3.14-3.06 (m, 1H), 3.05-2.97 (m, 1H), 2.34-2.20 (m, 3H), 2.18-2.03 (m, 1H), 2.03-1.69 (m, 7H), 1.69-1.49 (m, 6H), 1.49-1.25 (m, 5H), 1.17-1.06 (m, 1H), 1.03-1.01 (m, 3H), 1.01-0.93 (m, 1H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO8S [M-Na]− 544.3, found 544.2.
1H NMR (500 MHz, CD3OD) δ 4.35-4.27 (m, 1H), 4.00-3.92 (m, 1H), 3.83-3.77 (m, 1H), 3.76-3.64 (m, 2H), 3.41-3.32 (m, 1H), 3.14-3.06 (m, 1H), 3.05-2.98 (m, 1H), 2.34-2.20 (m, 3H), 2.18-2.03 (m, 1H), 2.03-1.69 (m, 7H), 1.69-1.49 (m, 6H), 1.49-1.24 (m, 5H), 1.17-1.06 (m, 1H), 1.03-0.94 (m, 4H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO8S [M-Na]− 544.3, found 544.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.28 (m, 1H), 4.00-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.32 (m, 1H), 2.91 (dt, J=10.3, 4.0 Hz, 1H), 2.34-2.12 (m, 5H), 2.07-1.69 (m, 10H), 1.68-1.25 (m, 15H), 1.16-1.06 (m, 1H), 1.04 (d, J=6.4 Hz, 3H), 0.98 (td, J=14.2, 3.4 Hz, 1H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO7S [M-Na]− 568.3, found 568.3.
1H NMR (500 MHz, CD3OD) δ 4.33-4.27 (m, 1H), 3.98-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.32 (m, 1H), 2.91 (dt, J=10.1, 4.1 Hz, 1H), 2.37-2.18 (m, 4H), 2.14 (ddd, J=14.2, 9.9, 6.5 Hz, 1H), 2.07-1.70 (m, 10H), 1.69-1.27 (m, 15H), 1.17-1.06 (m, 1H), 1.03 (d, J=6.5 Hz, 3H), 0.98 (td, J=14.1, 3.5 Hz, 1H), 0.92 (s, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C30H50N7S [M-Na]− 568.3, found 568.3.
1H NMR (400 MHz, DMSO-d6) δ 7.67 (d, J=7.4 Hz, 1H), 4.31 (d, J=4.3 Hz, 1H), 4.10 (s, 1H), 4.04-3.91 (m, 2H), 3.78 (s, 1H), 3.61 (s, 1H), 3.24-3.11 (m, 1H), 2.60 (dd, J=13.4, 4.6 Hz, 1H), 2.48-2.41 (m, 1H), 2.29-2.08 (m, 2H), 2.07-1.52 (m, 9H), 1.52-1.06 (m, 14H), 1.02-0.73 (m, 8H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.2.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.99-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.33 (m, 1H), 3.08-3.02 (m, 1H), 2.91-2.84 (m, 1H), 2.34-2.19 (m, 3H), 2.13-2.04 (m, 1H), 2.04-1.69 (m, 7H), 1.69-1.48 (m, 6H), 1.48-1.25 (m, 8H), 1.11 (qd, J=11.9, 5.8 Hz, 1H), 1.02 (d, J=6.4 Hz, 3H), 1.01-0.93 (m, 1H), 0.92 (s, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C27H46NO7S [M-Na]− 528.3, found 528.2.
1H NMR (500 MHz, CD3OD) δ 4.39-4.31 (m, 1H), 3.98-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.32 (m, 1H), 3.03 (dd, J=14.0, 5.5 Hz, 1H), 2.90 (dd, J=14.0, 6.3 Hz, 1H), 2.34-2.19 (m, 3H), 2.15-2.05 (m, 1H), 2.04-1.49 (m, 16H), 1.49-1.25 (m, 5H), 1.11 (qd, J=12.0, 5.7 Hz, 1H), 1.03 (d, J=6.5 Hz, 3H), 1.01-0.90 (m, 10H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO7S [M-Na]− 570.3, found 570.3.
1H NMR (500 MHz, CD3OD) δ 4.42-4.33 (m, 1H), 3.99-3.93 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.32 (m, 1H), 3.01 (dd, J=14.0, 5.5 Hz, 1H), 2.90 (dd, J=14.0, 6.4 Hz, 1H), 2.34-2.19 (m, 3H), 2.17-2.06 (m, 1H), 2.04-1.49 (m, 16H), 1.49-1.23 (m, 5H), 1.10 (qd, J=12.0, 5.9 Hz, 1H), 1.03 (d, J=6.5 Hz, 3H), 1.01-0.89 (m, 10H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO7S [M-Na]− 570.3, found 570.3.
1H NMR (400 MHz, DMSO-d6) δ 7.78 (s, 1H), 4.31 (d, J=4.4 Hz, 1H), 4.09 (d, J=3.4 Hz, 1H), 4.01 (d, J=3.3 Hz, 1H), 3.77 (s, 1H), 3.61 (s, 1H), 3.22-3.11 (m, 1H), 2.70-2.59 (m, 2H), 2.28-2.08 (m, 2H), 2.04-1.91 (m, 2H), 1.90-1.52 (m, 7H), 1.49-1.06 (m, 11H), 1.01-0.72 (m, 10H), 0.61-0.50 (m, 5H); LCMS (ESI) m/z calcd for C28H46NO7S [M-Na]− 540.3, found 540.2.
1H NMR (500 MHz, CD3OD) δ 3.99-3.93 (m, 1H), 3.89-3.32 (m, 7H), 2.47-2.18 (m, 6H), 2.05-1.70 (m, 7H), 1.69-1.26 (m, 11H), 1.18-0.94 (m, 5H), 0.92 (s, 3H), 0.724 (s, 1.5H), 0.719 (s, 1.5H); LCMS (ESI) m/z calcd for C28H46NO7S [M-Na]− 540.3, found 540.2.
1H NMR (500 MHz, CD3OD) δ 3.98-3.93 (m, 1H), 3.89-3.32 (m, 7H), 2.47-2.18 (m, 6H), 2.06-1.70 (m, 7H), 1.70-1.50 (m, 6H), 1.49-1.26 (m, 5H), 1.18-0.95 (m, 5H), 0.92 (s, 3H), 0.723 (s, 1.5H), 0.720 (s, 1.5H); LCMS (ESI) m/z calcd for C28H46NO7S [M-Na]− 540.3, found 540.2.
1H NMR (400 MHz, DMSO-d6) δ 4.30 (s, 1H), 4.12 (s, 1H), 4.01 (s, 1H), 3.79 (s, 1H), 3.61 (s, 1H), 3.54-3.39 (m, 2H), 3.31-3.23 (m, 2H), 3.21-3.12 (m, 1H), 2.70-2.61 (m, 1H), 2.60-2.53 (m, 1H), 2.39-2.06 (m, 12H), 2.03-1.92 (m, 1H), 1.85-1.56 (m, 6H), 1.50-1.07 (m, 11H), 1.01-0.82 (m, 5H), 0.81 (s, 3H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C30H53N2O7S [M-Na]− 585.4, found 585.3.
1H NMR (400 MHz, DMSO-d6) δ8.51-8.38 (m, 2H), 7.62-7.54 (m, 1H), 7.43-7.29 (m, 1H), 4.65 (s, 0.5H), 4.59-4.45 (m, 1.5H), 4.30 (s, 1H), 4.16-3.97 (m, 2H), 3.82-3.72 (m, 1H), 3.61 (s, 1H), 3.54-3.41 (m, 2H), 3.22-3.11 (m, 1H), 2.69-2.54 (m, 2H), 2.48-2.37 (m, 1H), 2.37-2.07 (m, 3H), 2.04-1.90 (m, 1H), 1.85-1.55 (m, 6H), 1.50-1.07 (m, 11H), 0.96 (d, J=6.3 Hz, 3H), 0.89-0.73 (m, 5H), 0.62-0.52 (m, 3H); LCMS (ESI) m/z calcd for C32H49N2O7S [M-Na]− 605.3, found 605.3.
1H NMR (500 MHz, CD3OD) δ7.52-7.46 (m, 2H), 7.44-7.38 (m, 1H), 7.34-7.29 (m, 2H), 4.13-4.06 (m, 2H), 3.87-3.83 (m, 1H), 3.79-3.75 (m, 1H), 3.39-3.33 (m, 1H), 3.09-3.03 (m, 2H), 2.32-2.09 (m, 3H), 2.05-1.87 (m, 3H), 1.82-1.47 (m, 11H), 1.46-1.32 (m, 2H), 1.32-1.14 (m, 3H), 1.13-1.01 (m, 1H), 1.01-0.92 (m, 1H), 0.90 (s, 3H), 0.77 (d, J=6.1 Hz, 3H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C32H48NO7S [M-Na]− 590.3, found 590.3.
1H NMR (500 MHz, CD3OD) δ 3.39 (t, J=7.0 Hz, 2H), 2.82 (d, J=13.5 Hz, 1H), 2.51-2.40 (m, 1H), 2.34 (t, J=7.0 Hz, 2H), 2.22 (ddd, J=13.8, 10.4, 5.2 Hz, 1H), 2.12-2.01 (m, 4H), 1.99-1.86 (m, 2H), 1.82-1.72 (m, 2H), 1.68-1.57 (m, 2H), 1.54-1.07 (m, 15H), 1.04 (s, 3H), 0.96 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C27H42NO4 [M-Na]− 444.3, found 444.2.
1H NMR (400 MHz, DMSO-d6) δ3.57-3.41 (m, 2H), 2.93 (s, 1.5H), 2.82-2.69 (m, 2.5H), 2.69-2.61 (m, 1H), 2.59-2.52 (m, 1H), 2.42-2.06 (m, 3H), 2.01-1.88 (m, 3H), 1.86-1.48 (m, 7H), 1.46-0.99 (m, 14H), 0.95 (s, 3H), 0.89 (d, 3H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (500 MHz, CD3OD) δ 7.41-7.34 (m, 1H), 7.34-7.19 (m, 4H), 4.74 (s, 1H), 4.63 (s, 1H), 3.84-3.69 (m, 2H), 3.07 (t, J=7.1 Hz, 1H), 3.03-2.98 (m, 1H), 2.90-2.79 (m, 1H), 2.62-2.52 (m, 0.5H), 2.52-2.35 (m, 2H), 2.32-2.20 (m, 0.5H), 2.14-1.70 (m, 8H), 1.69-0.93 (m, 20.5H), 0.86 (d, J=6.5 Hz, 1.5H), 0.74 (s, 1.5H), 0.69 (s, 1.5H); LCMS (ESI) m/z calcd for C33H48NO5S [M-Na]− 570.3, found 570.3.
1H NMR (500 MHz, CD3OD) δ3.89-3.79 (m, 1H), 3.76-3.64 (m, 3H), 3.58-3.52 (m, 1H), 3.50-3.45 (m, 1H), 3.13-3.04 (m, 2H), 2.89-2.79 (m, 1H), 2.57-2.41 (m, 2H), 2.41-2.29 (m, 1H), 2.12-2.02 (m, 3H), 1.99-1.88 (m, 3H), 1.83-1.72 (m, 2H), 1.69-1.56 (m, 2H), 1.56-1.08 (m, 14H), 1.05 (s, 3H), 1.02-0.93 (m, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C28H46NO6S [M-Na]− 524.3, found 524.3.
1H NMR (500 MHz, CD3OD) δ4.66-4.56 (m, 0.5H), 4.23-4.12 (m, 0.5H), 3.71-3.64 (m, 1H), 3.64-3.57 (m, 1H), 3.09-3.02 (m, 2H), 2.84 (td, J=14.3, 3.7 Hz, 1H), 2.52-2.40 (m, 2H), 2.37-2.26 (m, 1H), 2.13-2.01 (m, 3H), 2.00-1.86 (m, 3H), 1.84-1.71 (m, 2H), 1.69-1.57 (m, 2H), 1.56-1.07 (m, 20H), 1.048 (s, 1.5H), 1.045 (s, 1.5H), 1.02-0.93 (m, 3H), 0.74 (s, 1.5H), 0.73 (s, 1.5H); LCMS (ESI) m/z calcd for C29H48NO5 [M-Na]− 522.3, found 522.3.
1H NMR (500 MHz, CD3OD) δ 4.44 (tt, J=12.1, 3.9 Hz, 0.5H), 4.06-3.90 (m, 2.5H), 3.75-3.61 (m, 2H), 3.53-3.42 (m, 2H), 3.08-3.00 (m, 2H), 2.83 (td, J=14.2, 3.5 Hz, 1H), 2.54-2.30 (m, 3H), 2.12-2.02 (m, 3H), 2.02-1.84 (m, 5H), 1.83-1.71 (m, 1H), 1.71-1.24 (m, 15H), 1.24-1.08 (m, 4H), 1.05 (s, 1.5H), 1.04 (s, 1.5H), 1.02-0.93 (m, 3H), 0.74 (s, 1.5H), 0.73 (s, 1.5H); LCMS (ESI) m/z calcd for C31H50NO6S [M-Na]− 564.3, found 564.3.
1H NMR (500 MHz, CD3OD) δ 5.02 (d, J=10.2 Hz, 0.4H), 4.42 (d, J=13.3 Hz, 0.6H), 4.32-4.25 (m, 0.6H), 3.92 (d, J=13.0 Hz, 0.4H), 3.24 (dd, J=13.5, 11.1 Hz, 0.6H), 3.01 (td, J=13.2, 2.8 Hz, 0.4H), 2.90-2.57 (m, 3H), 2.56-2.39 (m, 2H), 2.38-2.25 (m, 2H), 2.13-1.99 (m, 3H), 1.99-1.69 (m, 7H), 1.69-1.57 (m, 2H), 1.57-1.24 (m, 11H), 1.24-1.07 (m, 4H), 1.05 (s, 3H), 1.01-0.98 (m, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C29H46NO5S [M-Na]− 520.3, found 520.3.
1H NMR (500 MHz, CD3OD) δ5.02 (d, J=9.9 Hz, 0.4H), 4.44 (d, J=13.0 Hz, 0.6H), 4.33-4.25 (m, 0.6H), 3.92 (d, J=13.5 Hz, 0.4H), 3.23 (dd, J=13.5, 11.2 Hz, 0.6H), 3.01 (td, J=13.2, 2.8 Hz, 0.4H), 2.89-2.55 (m, 3H), 2.52-2.40 (m, 2H), 2.40-2.25 (m, 2H), 2.12-1.99 (m, 3H), 1.99-1.70 (m, 7H), 1.69-1.58 (m, 2H), 1.56-1.24 (m, 11H), 1.24-1.07 (m, 4H), 1.05 (s, 3H), 1.01-0.98 (m, 3H), 0.74 (s, 3H); LCMS (ESI) m/z calcd for C29H46NO5S [M-Na]− 520.3, found 520.3.
1H NMR (400 MHz, DMSO-d6) δ 4.37 (d, J=12.9 Hz, 1H), 3.85 (d, J=13.4 Hz, 1H), 2.98-2.87 (m, 1H), 2.81-2.69 (m, 1H), 2.48-2.11 (m, 5H), 2.01-1.67 (m, 9H), 1.67-1.49 (m, 3H), 1.46-1.00 (m, 16H), 0.96 (s, 3H), 0.90 (d, J=6.5 Hz, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C29H46NO5S [M-Na]− 520.3, found 520.2.
1H NMR (400 MHz, DMSO-d6) δ 4.16 (td, J=8.4, 2.3 Hz, 1H), 4.05-3.97 (m, 1H), 3.85 (t, J=9.0 Hz, 1H), 3.80-3.71 (m, 1H), 3.46-3.38 (m, 1H), 2.75 (t, J=14.1 Hz, 1H), 2.36 (td, J=14.7, 5.4 Hz, 1H), 2.05-1.67 (m, 9H), 1.66-1.49 (i, 3H), 1.47-0.99 (m, 14H), 0.96 (s, 3H), 0.88 (d, J=6.7 Hz, 3H), 0.64 (d, J=2.0 Hz, 3H); LCMS (ESI) m/z calcd for C27H42NO5S [M-Na]− 492.3, found 492.2.
1H NMR (500 MHz, CD3OD) δ 3.15-3.10 (m, 2H), 2.89-2.80 (m, 1H), 2.52-2.42 (m, 1H), 2.20 (ddd, J=14.0, 10.3, 5.2 Hz, 1H), 2.13-1.99 (m, 4H), 1.99-1.85 (m, 3H), 1.83-1.71 (m, 2H), 1.68-1.57 (m, 2H), 1.56-1.24 (m, 10H), 1.53 (s, 6H), 1.24-1.07 (m, 4H), 1.04 (s, 3H), 0.96 (d, J=6.6 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C28H46NO5S [M-Na]− 508.3, found 508.3.
1H NMR (500 MHz, CD3OD) 7.30-7.22 (m, 4H), 7.21-7.14 (u, 1H), 4.50-4.43 (m, 1H), 3.16 (dd, J=13.6, 6.3 Hz, 1H), 3.04-2.94 (m, 2H), 2.91 (dd, J=13.6, 7.8 Hz, 1H), 2.88-2.80 (m, 1H), 2.52-2.41 (m, 1H), 2.17 (ddd, J=13.8, 10.7, 5.2 Hz, 1H), 2.12-1.83 (m, 7H), 1.82-1.75 (m, 1H), 1.73-1.57 (m, 3H), 1.56-1.06 (m, 14H), 1.04 (s, 3H), 0.93 (d, J=6.6 Hz, 3H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C33H48NO5S [M-Na]− 570.3, found 570.3.
1H NMR (500 MHz, CD3OD) δ7.30-7.22 (m, 4H), 7.22-7.14 (m, 1H), 4.52-4.44 (m, 1H), 3.16 (dd, J=13.6, 6.1 Hz, 1H), 3.03-2.94 (m, 2H), 2.91 (dd, J=13.6, 7.8 Hz, 1H), 2.88-2.80 (m, 1H), 2.52-2.41 (m, 1H), 2.18 (ddd, J=13.8, 10.4, 5.1 Hz, 1H), 2.13-1.83 (m, 7H), 1.83-1.75 (m, 1H), 1.74-1.56 (m, 3H), 1.56-1.07 (m, 14H), 1.04 (s, 3H), 0.92 (d, J=6.6 Hz, 3H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C33H48NO5S [M-Na]− 570.3, found 570.4.
1H NMR (500 MHz, CD3OD) δ 4.23-4.16 (m, 1H), 2.96 (dd, J=6.1, 1.9 Hz, 2H), 2.88-2.80 (m, 1H), 2.52-2.41 (m, 1H), 2.28 (ddd, J=13.8, 10.6, 5.2 Hz, 1H), 2.15-2.02 (m, 5H), 1.99-1.87 (m, 3H), 1.87-1.75 (m, 2H), 1.69-1.56 (m, 2H), 1.56-1.07 (m, 14H), 1.05 (s, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.92 (t, J=6.5 Hz, 6H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (400 MHz, DMSO-d6) δ 7.47 (d, J=8.5 Hz, 1H), 3.99-3.88 (m, 1H), 2.75 (t, J=14.1 Hz, 1H), 2.56-2.51 (m, 2H), 2.36 (td, J=14.5, 5.3 Hz, 1H), 2.14-1.89 (m, 6H), 1.87-1.62 (m, 5H), 1.62-1.49 (m, 2H), 1.46-0.98 (m, 14H), 0.95 (s, 3H), 0.89 (d, J=6.5 Hz, 3H), 0.76 (d, J=6.8 Hz, 6H), 0.63 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5S [M-Na]− 522.3, found 522.3.
1H NMR (500 MHz, CD3OD) δ 7.37-7.27 (m, 4H), 7.24-7.18 (m, 1H), 5.34 (dd, J=10.0, 3.7 Hz, 1H), 3.26 (dd, J=14.3, 10.0 Hz, 1H), 3.09 (dd, J=14.3, 3.8 Hz, 1H), 2.89-2.79 (m, 1H), 2.51-2.41 (m, 1H), 2.31 (ddd, J=14.0, 10.2, 5.3 Hz, 1H), 2.15 (ddd, J=14.0, 10.0, 6.5 Hz, 1H), 2.11-2.00 (m, 3H), 2.00-1.84 (m, 3H), 1.83-1.74 (m, 2H), 1.65-1.56 (m, 2H), 1.55-1.06 (m, 14H), 1.04 (s, 3H), 0.95 (d, J=6.5 Hz, 3H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C32H46NO5S [M-Na]− 556.3, found 556.3.
1H NMR (500 MHz, CD3OD) δ 7.36-7.27 (m, 4H), 7.24-7.19 (m, 1H), 5.35 (dd, J=10.1, 3.6 Hz, 1H), 3.26 (dd, J=14.3, 10.1 Hz, 1H), 3.09 (dd, J=14.3, 3.7 Hz, 1H), 2.88-2.80 (m, 1H), 2.51-2.41 (m, 1H), 2.30 (ddd, J=13.8, 9.7, 5.0 Hz, 1H), 2.17 (ddd, J=13.9, 9.3, 7.1 Hz, 1H), 2.12-2.00 (m, 3H), 1.99-1.83 (m, 3H), 1.83-1.73 (m, 2H), 1.71-1.55 (m, 2H), 1.55-1.06 (m, 14H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.67 (s, 3H); LCMS (ESI) m/z calcd for C32H46NO5S [M-Na]− 556.3, found 556.3.
1H NMR (500 MHz, CD3OD) δ 4.52-4.45 (m, 0.5H), 4.43-4.36 (m, 0.5H), 3.58-3.51 (m, 0.5H), 3.50-3.28 (m, 2H), 3.02-2.90 (m, 1H), 2.85 (td, J=14.2, 4.1 Hz, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.56 (ddd, J=15.3, 10.6, 5.3 Hz, 0.5H), 2.51-2.27 (m, 3H), 2.20 (ddd, J=14.7, 10.4, 5.9 Hz, 0.5H), 2.12-1.87 (m, 9H), 1.85-1.71 (m, 2H), 1.69-1.57 (m, 2H), 1.56-1.07 (m, 14H), 1.05 (s, 1.5H), 1.04 (s, 1.5H), 1.00 (d, J=6.6 Hz, 1.5H), 0.98 (d, J=6.6 Hz, 1.5H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C29H46NO5S [M-Na]− 520.3, found 520.3.
1H NMR (400 MHz, DMSO-d6) δ4.24-4.10 (m, 1H), 3.42-3.27 (m, 1H), 3.27-3.11 (m, 1H), 2.91 (dd, J=12.7, 2.9 Hz, 0.5H), 2.76 (td, J=14.1, 6.4 Hz, 1H), 2.60-2.52 (m, 0.5H), 2.43-2.03 (m, 5H), 2.00-1.89 (m, 3H), 1.88-1.48 (m, 10H), 1.47-0.99 (m, 14H), 0.96 (s, 3H), 0.93-0.86 (m, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C29H46NO5S [M-Na]− 520.3, found 520.4.
1H NMR (500 MHz, CD3OD) δ 3.57 (dd, J=13.8, 6.1 Hz, 1H), 3.44 (dd, J=13.8, 6.7 Hz, 1H), 3.00-2.90 (m, 1H), 2.89-2.80 (m, 1H), 2.52-2.41 (m, 1H), 2.26 (ddd, J=13.9, 10.2, 5.2 Hz, 1H), 2.17-2.02 (m, 4H), 1.99-1.85 (m, 3H), 1.85-1.75 (m, 2H), 1.68-1.57 (m, 2H), 1.57-1.24 (m, 13H), 1.24-1.07 (m, 4H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (400 MHz, DMSO-d6) δ 7.59 (t, J=5.6 Hz, 1H), 3.28-3.20 (m, 1H), 3.19-3.09 (m, 1H), 2.75 (t, J=14.1 Hz, 1H), 2.48-2.30 (m, 2H), 2.07 (ddd, J=14.6, 9.9, 5.2 Hz, 1H), 2.00-1.88 (m, 4H), 1.87-1.49 (m, 7H), 1.47-1.04 (m, 14H), 1.02 (d, J=6.8 Hz, 3H), 0.96 (s, 3H), 0.88 (d, J=6.5 Hz, 3H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.26 (m, 1H), 3.75-3.64 (m, 2H), 3.14-3.06 (m, 1H), 3.06-2.98 (m, 1H), 2.89-2.79 (m, 1H), 2.51-2.40 (m, 1H), 2.33-2.23 (m, 1H), 2.16-1.99 (m, 4H), 1.99-1.87 (m, 3H), 1.85-1.74 (m, 2H), 1.68-1.56 (m, 2H), 1.56-1.24 (m, 10H), 1.24-1.06 (m, 4H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO6S [M-Na]− 510.3, found 510.2.
1H NMR (500 MHz, CD3OD) δ 4.33-4.26 (m, 1H), 3.76-3.65 (m, 2H), 3.13-3.00 (m, 2H), 2.89-2.80 (m, 1H), 2.51-2.40 (m, 1H), 2.32-2.24 (m, 1H), 2.16-2.00 (m, 4H), 1.99-1.86 (m, 3H), 1.85-1.74 (m, 2H), 1.68-1.57 (m, 2H), 1.56-1.24 (m, 10H), 1.24-1.06 (m, 6H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO6S [M-Na]− 510.3, found 510.3.
1H NMR (500 MHz, CD3OD) δ 4.34-4.28 (m, 1H), 2.91 (dt, J=10.2, 4.0 Hz, 1H), 2.88-2.80 (m, 1H), 2.52-2.42 (m, 1H), 2.32-1.84 (m, 12H), 1.84-1.74 (m, 2H), 1.69-1.57 (m, 2H), 1.57-1.24 (m, 14H), 1.24-1.06 (m, 4H), 1.04 (s, 3H), 0.98 (d, J=6.5 Hz, 3H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C30H48NO5S [M-Na]− 534.3, found 534.4.
1H NMR (500 MHz, CD3OD) δ 4.33-4.26 (m, 1H), 2.91 (dt, J=10.1, 4.1 Hz, 1H), 2.88-2.80 (m, 1H), 2.51-2.41 (m, 1H), 2.31 (ddd, J=14.2, 10.4, 5.2 Hz, 1H), 2.26-2.18 (m, 1H), 2.16-1.74 (m, 12H), 1.69-1.57 (m, 2H), 1.57-1.24 (m, 14H), 1.24-1.06 (m, 4H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C30H48NO5S [M-Na]− 534.3, found 534.3.
1H NMR (500 MHz, CD3OD) δ 4.37-4.26 (m, 1H), 3.05 (dd, J=13.9, 5.6 Hz, 1H), 2.92-2.80 (m, 2H), 2.52-2.41 (m, 1H), 2.22 (ddd, J=13.8, 10.3, 5.2 Hz, 1H), 2.13-2.01 (m, 4H), 1.99-1.85 (m, 3H), 1.84-1.74 (m, 2H), 1.68-1.57 (m, 2H), 1.56-1.24 (m, 13H), 1.23-1.07 (m, 4H), 1.05 (s, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (400 MHz, DMSO-d6) δ 7.68 (d, J=7.5 Hz, 1H), 4.04-3.92 (m, 1H), 2.81-2.69 (m, 1H), 2.60 (dd, J=13.4, 4.6 Hz, 1H), 2.49-2.30 (m, 2H), 2.09-1.48 (m, 12H), 1.47-0.99 (m, 17H), 0.96 (s, 3H), 0.88 (d, J=6.5 Hz, 3H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C27H44NO5S [M-Na]− 494.3, found 494.2.
1H NMR (500 MHz, CD3OD) δ 4.39-4.30 (m, 1H), 3.03 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.2 Hz, 1H), 2.87-2.79 (m, 1H), 2.51-2.40 (m, 1H), 2.24 (ddd, J=13.8, 9.9, 5.3 Hz, 1H), 2.14-2.02 (m, 4H), 1.99-1.87 (m, 3H), 1.84-1.75 (m, 2H), 1.71-1.24 (m, 15H), 1.23-1.07 (m, 4H), 1.05 (s, 3H), 1.00-0.91 (m, 9H), 0.73 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO5S [M-Na]− 536.3, found 536.3.
1H NMR (500 MHz, CD3OD) δ 4.42-4.33 (m, 1H), 3.01 (dd, J=14.1, 5.6 Hz, 1H), 2.94-2.80 (m, 2H), 2.52-2.41 (m, 1H), 2.22 (ddd, J=14.2, 9.4, 5.2 Hz, 1H), 2.15-2.02 (m, 4H), 1.99-1.85 (m, 3H), 1.85-1.75 (m, 2H), 1.71-1.06 (m, 19H), 1.05 (s, 3H), 1.00-0.91 (m, 9H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO5S [M-Na]− 536.3, found 536.3.
1H NMR (500 MHz, CD3OD) δ 3.08-2.97 (m, 2H), 2.88-2.80 (m, 1H), 2.52-2.41 (m, 1H), 2.20 (ddd, J=14.0, 10.4, 5.2 Hz, 1H), 2.12-2.00 (m, 4H), 1.99-1.86 (m, 3H), 1.83-1.71 (m, 2H), 1.68-1.57 (m, 2H), 1.57-1.24 (m, 10H), 1.23-1.07 (m, 4H), 1.04 (s, 3H), 1.01-0.90 (m, 5H), 0.80-0.76 (m, 2H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C28H44NO5S [M-Na]− 506.3, found 506.2.
1H NMR (400 MHz, DMSO-d6) δ 3.65-3.26 (m, 3.5H), 3.25-3.13 (m, 1H), 3.13-3.04 (m, 0.5H), 2.81-2.69 (m, 1H), 2.43-2.30 (m, 1H), 2.27-2.14 (m, 1H), 2.14-1.86 (m, 6H), 1.86-1.50 (m, 7H), 1.46-1.00 (m, 14H), 0.96 (s, 3H), 0.93-0.82 (m, 3H), 0.68-0.60 (m, 3H); LCMS (ESI) m/z calcd for C28H44NO5S [M-Na]− 506.3, found 506.3.
1H NMR (400 MHz, DMSO-d6) δ 3.64-3.30 (m, 3.5H), 3.25-3.15 (m, 1H), 3.12-3.03 (m, 0.5H), 2.81-2.69 (m, 1H), 2.43-2.30 (m, 1H), 2.26-2.14 (m, 1H), 2.14-1.86 (m, 6H), 1.86-1.49 (m, 7H), 1.49-1.00 (m, 14H), 0.96 (s, 3H), 0.92-0.83 (m, 3H), 0.66-0.62 (m, 3H); LCMS (ESI) m/z calcd for C28H44NO5S [M-Na]− 506.3, found 506.3.
1H NMR (400 MHz, DMSO-d6) δ3.55-3.39 (m, 2H), 3.32-3.22 (m, 2H), 2.82-2.70 (m, 1H), 2.70-2.61 (m, 1.2H), 2.60-2.54 (m, 0.8H), 2.43-2.18 (m, 5H), 2.16 (s, 2.4H), 2.12 (s, 3.6H), 2.00-1.90 (m, 3H), 1.87-1.50 (m, 7H), 1.47-0.99 (m, 14H), 0.96 (s, 3H), 0.91-0.87 (m, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C30H51N2O5S [M-Na]− 551.4, found 551.3.
1H NMR (500 MHz, CD3OD) δ8.52-8.42 (m, 2H), 7.80-7.77 (m, 0.6H), 7.77-7.72 (m, 0.4H), 7.50-7.44 (m, 0.4H), 7.43-7.38 (m, 0.6H), 4.84-4.79 (m, 0.8H), 4.71-4.62 (m, 1.2H), 3.82-3.71 (m, 2H), 3.11-3.04 (m, 2H), 2.85-2.78 (m, 1H), 2.63-2.55 (m, 0.6H), 2.51-2.37 (m, 2H), 2.35-2.26 (m, 0.4H), 2.12-1.72 (m, 7H), 1.69-1.56 (m, 2H), 1.55-1.06 (m, 14.6H), 1.05 (s, 1.8H), 1.03 (s, 1.2H), 1.01 (d, J=6.5 Hz, 1.8H), 0.99-0.93 (m, 0.4H), 0.88 (d, J=6.5 Hz, 1.2H), 0.74 (s, 1.8H), 0.70 (s, 1.2H); LCMS (ESI) m/z calcd for C32H47N2O5S [M-Na]− 571.3, found 571.4.
1H NMR (500 MHz, CD3OD) δ 7.53-7.47 (m, 2H), 7.46-7.39 (m, 1H), 7.35-7.29 (m, 2H), 4.15-4.05 (m, 2H), 3.09-3.02 (m, 2H), 2.82 (t, J=14.3 Hz, 1H), 2.43 (td, J=14.7, 5.6 Hz, 1H), 2.17-2.02 (m, 3H), 2.02-1.85 (m, 4H), 1.82-1.64 (m, 3H), 1.61-0.91 (m, 19H), 0.71 (d, J=6.2 Hz, 3H), 0.65 (s, 3H); LCMS (ESI) m/z calcd for C32H46NO5S [M-Na]− 556.3, found 556.3.
1H NMR (500 MHz, CD3OD) δ 3.65 (t, J=2.6 Hz, 1H), 3.39 (t, J=7.0 Hz, 2H), 3.34-3.26 (m, 1H), 2.34 (t, J=7.0 Hz, 2H), 2.23 (ddd, J=13.8, 10.4, 5.2 Hz, 1H), 2.07 (ddd, J=13.8, 10.0, 6.4 Hz, 1H), 2.00 (dt, J=12.4, 3.4 Hz, 1H), 1.97-1.68 (m, 7H), 1.64-1.24 (m, 13H), 1.23-1.06 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO5 [M-Na]− 490.4, found 490.3.
1H NMR (500 MHz, CD3OD) δ 3.65 (t, J=2.8 Hz, 1H), 3.58 (t, J=6.3 Hz, 2H), 3.35-3.27 (m, 1H), 3.27-3.22 (m, 2H), 2.24 (ddd, J=13.7, 10.0, 5.2 Hz, 1H), 2.10 (ddd, J=13.8, 9.7, 6.7 Hz, 1H), 2.00 (dt, J=12.5, 3.4 Hz, 1H), 1.97-1.66 (m, 9H), 1.64-1.25 (m, 12H), 1.24-1.06 (m, 3H), 1.06-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO4 [M-H]− 476.4, found 476.4.
1H NMR (500 MHz, CD3OD) δ 3.84-3.70 (m, 2H), 3.66 (t, J=2.6 Hz, 1H), 3.35-3.25 (m, 1H), 3.12 (s, 1.5H), 3.09-2.99 (m, 2H), 2.93 (s, 1.5H), 2.52 (ddd, J=15.6, 10.9, 5.1 Hz, 0.5H), 2.46-2.33 (m, 1H), 2.26 (ddd, J=15.3, 10.7, 5.7 Hz, 0.5H), 2.04-1.69 (m, 8H), 1.63-1.26 (m, 13H), 1.25-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.3.
1H NMR (400 MHz, DMSO-d6) δ 7.41-7.14 (m, 5H), 4.59-4.48 (m, 2H), 4.28 (d, J=4.8 Hz, 1H), 4.08-4.03 (m, 1H), 3.54-3.39 (m, 3H), 3.17-3.05 (m, 1H), 2.64-2.51 (m, 2H), 2.45-2.10 (m, 2H), 1.97-1.59 (m, 7H), 1.55-0.74 (m, 27H), 0.62 (s, 2H), 0.57 (s, 1H); LCMS (ESI) m/z calcd for C35H54NO6S [M-Na]− 616.4, found 616.3.
1H NMR (500 MHz, CD3OD) δ 3.89-3.78 (m, 1H), 3.78-3.63 (m, 4H), 3.58-3.51 (m, 1H), 3.51-3.43 (m, 1H), 3.35-3.26 (m, 1H), 3.14-3.03 (m, 2H), 2.57-2.44 (m, 1H), 2.42-2.29 (m, 1H), 2.05-1.69 (m, 8H), 1.64-1.25 (m, 13H), 1.25-1.05 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.86 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO7S [M-Na]− 570.3, found 570.4.
1H NMR (400 MHz, DMSO-d6) δ4.55-4.43 (m, 0.5H), 4.29 (t, J=5.7 Hz, 1H), 4.11-3.98 (m, 1.5H), 3.49 (s, 1H), 3.45-3.37 (m, 1H), 3.37-3.28 (m, 1H), 3.18-3.05 (m, 1H), 2.67-2.55 (m, 2H), 2.34-2.11 (m, 2H), 1.95-1.57 (m, 7H), 1.55-0.94 (m, 23H), 0.93-0.78 (m, 10H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C31H54NO6S [M-Na]− 568.4, found 568.4.
1H NMR (500 MHz, CD3OD) δ4.43 (tt, J=12.1, 3.9 Hz, 0.5H), 4.06-3.90 (m, 2.5H), 3.76-3.62 (m, 3H), 3.53-3.41 (m, 2H), 3.35-3.26 (m, 1H), 3.08-3.01 (m, 2H), 2.54-2.43 (m, 1H), 2.41-2.30 (m, 1H), 2.05-1.64 (m, 11H), 1.64-1.43 (m, 8H), 1.43-1.25 (m, 6H), 1.25-1.06 (m, 3H), 1.06-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.71 (s, 1.5H), 0.69 (s, 1.5H); LCMS (ESI) m/z calcd for C33H56NO7S [M-Na]− 610.4, found 610.4.
1H NMR (500 MHz, CD3OD) δ 5.05-4.99 (m, 0.5H), 4.43 (d, J=13.0 Hz, 0.5H), 4.33-4.25 (m, 0.5H), 3.92 (d, J=13.3 Hz, 0.5H), 3.65 (t, J=2.7 Hz, 1H), 3.35-3.27 (m, 1H), 3.27-3.20 (m, 0.5H), 3.06-2.96 (m, 0.5H), 2.84-2.56 (m, 2H), 2.56-2.40 (m, 1H), 2.38-2.23 (m, 2H), 2.04-1.69 (m, 10H), 1.64-1.26 (m, 14H), 1.25-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.4.
1H NMR (500 MHz, CD3OD) δ 5.02 (d, J=9.8 Hz, 0.5H), 4.44 (d, J=13.1 Hz, 0.5H), 4.34-4.26 (m, 0.5H), 3.92 (d, J=13.2 Hz, 0.5H), 3.66 (t, J=2.7 Hz, 1H), 3.34-3.26 (m, 1H), 3.23 (dd, J=13.5, 11.2 Hz, 0.5H), 3.01 (td, J=13.2, 2.8 Hz, 0.5H), 2.84-2.56 (m, 2H), 2.53-2.41 (m, 1H), 2.41-2.24 (m, 2H), 2.04-1.69 (m, 10H), 1.64-1.25 (m, 14H), 1.24-1.06 (m, 3H), 1.05-0.96 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.4.
1H NMR (400 MHz, DMSO-d6) δ 4.37 (d, J=13.1 Hz, 1H), 4.29 (d, J=4.7 Hz, 1H), 4.05 (d, J=4.1 Hz, 1H), 3.86 (d, J=13.4 Hz, 1H), 3.49 (s, 1H), 3.18-3.05 (m, 1H), 2.98-2.87 (m, 1H), 2.48-2.38 (m, 2H), 2.36-2.10 (m, 2H), 1.98-1.57 (m, 9H), 1.55-1.03 (m, 18H), 1.03-0.75 (m, 11H), 0.61 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.3.
1H NMR (500 MHz, CD3OD) δ 4.42 (t, J=8.8 Hz, 1H), 4.37-4.30 (m, 1H), 4.21-4.11 (m, 2H), 3.85-3.76 (m, 1H), 3.65 (t, J=2.6 Hz, 1H), 3.35-3.25 (m, 1H), 2.25-2.13 (m, 1H), 2.11-1.97 (m, 2H), 1.97-1.69 (m, 7H), 1.64-1.24 (m, 13H), 1.24-1.06 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6S [M-Na]− 538.3, found 538.3.
1H NMR (500 MHz, CD3OD) δ 3.65 (t, J=2.7 Hz, 1H), 3.34-3.25 (m, 1H), 3.20-3.10 (m, 2H), 2.20 (ddd, J=13.9, 10.3, 5.1 Hz, 1H), 2.09-1.68 (m, 9H), 1.64-1.23 (m, 19H), 1.23-1.05 (m, 3H), 1.05-0.94 (m, 4H), 0.93-0.86 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C30H52NO6S [M-Na]− 554.4, found 554.3.
1H NMR (400 MHz, DMSO-d6) δ 7.71 (d, J=7.6 Hz, 1H), 7.29-7.12 (m, 5H), 4.29 (d, J=4.6 Hz, 1H), 4.19-4.07 (m, 1H), 4.05 (d, J=5.0 Hz, 1H), 3.50 (s, 1H), 3.18-3.07 (m, 2H), 2.74 (dd, J=13.4, 7.1 Hz, 1H), 2.53 (d, J=6.2 Hz, 2H), 2.05-1.94 (m, 1H), 1.93-1.64 (m, 7H), 1.64-0.74 (m, 28H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C35H54NO6S [M-Na]− 616.4, found 616.4.
1H NMR (500 MHz, CD3OD) 7.30-7.22 (m, 4H), 7.21-7.14 (u, 1H), 4.52-4.43 (m, 1H), 3.65 (t, J=2.8 Hz, 1H), 3.34-3.26 (m, 1H), 3.16 (dd, J=13.6, 6.1 Hz, 1H), 3.03-2.94 (m, 2H), 2.91 (dd, J=13.7, 7.8 Hz, 1H), 2.18 (ddd, J=13.8, 10.3, 5.1 Hz, 1H), 2.07-1.95 (m, 2H), 1.95-1.65 (m, 7H), 1.64-1.05 (m, 16H), 1.00 (td, J=14.2, 3.5 Hz, 1H), 0.95-0.85 (m, 9H), 0.67 (s, 3H); LCMS (ESI) m/z calcd for C35H54NO6S [M-Na]− 616.4, found 616.4.
1H NMR (500 MHz, CD3OD) δ 4.24-4.16 (m, 1H), 3.65 (t, J=2.8 Hz, 1H), 3.35-3.26 (m, 1H), 2.98-2.93 (m, 2H), 2.29 (ddd, J=13.7, 10.6, 5.1 Hz, 1H), 2.15-2.03 (m, 2H), 2.03-1.69 (m, 8H), 1.63-1.25 (m, 13H), 1.24-1.05 (m, 3H), 1.05-0.96 (m, 4H), 0.95-0.87 (m, 12H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C31H54NO6S [M-Na]− 568.4, found 568.4.
1H NMR (500 MHz, CD3OD) δ 4.25-4.18 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.35-3.26 (m, 1H), 2.95 (d, J=6.1 Hz, 2H), 2.26 (ddd, J=13.7, 9.7, 5.0 Hz, 1H), 2.20-2.04 (m, 2H), 2.04-1.69 (m, 8H), 1.63-1.24 (m, 13H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.95-0.85 (m, 12H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C31H54NO6S [M-Na]− 568.4, found 568.4.
1H NMR (400 MHz, DMSO-d6) δ 8.15 (d, J=6.3 Hz, 1H), 7.29-7.19 (m, 4H), 7.18-7.11 (m, 1H), 5.03-4.93 (m, 1H), 4.29 (d, J=4.7 Hz, 1H), 4.05 (d, J=5.0 Hz, 1H), 3.49 (s, 1H), 3.18-3.05 (m, 1H), 2.85 (dd, J=13.9, 9.1 Hz, 1H), 2.67 (dd, J=13.8, 4.1 Hz, 1H), 2.17-2.05 (m, 1H), 2.01-1.58 (m, 8H), 1.57-0.74 (m, 27H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO6S [M-Na]− 602.4, found 602.4.
1H NMR (500 MHz, CD3OD) δ7.37-7.26 (m, 4H), 7.25-7.18 (m, 1H), 5.36 (dd, J=10.0, 3.7 Hz, 1H), 3.64 (t, J=2.7 Hz, 1H), 3.34-3.22 (m, 2H), 3.09 (dd, J=14.3, 3.7 Hz, 1H), 2.30 (ddd, J=14.3, 9.6, 5.0 Hz, 1H), 2.18 (ddd, J=13.9, 9.1, 7.2 Hz, 1H), 1.98 (dt, J=12.4, 3.4 Hz, 1H), 1.95-1.67 (m, 7H), 1.64-1.11 (m, 15H), 1.10-0.99 (m, 2H), 0.97 (d, J=6.4 Hz, 3H), 0.93-0.87 (m, 6H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO6S [M-Na]− 602.4, found 602.4.
1H NMR (500 MHz, CD3OD) δ 4.52-4.45 (m, 0.5H), 4.44-4.37 (m, 0.5H), 3.66 (t, J=2.7 Hz, 1H), 3.58-3.52 (m, 0.5H), 3.50-3.27 (m, 3H), 3.02-2.90 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.56 (ddd, J=15.3, 10.6, 5.2 Hz, 0.5H), 2.48-2.27 (m, 2H), 2.20 (ddd, J=14.6, 10.4, 5.9 Hz, 0.5H), 2.11-1.70 (m, 11H), 1.64-1.25 (m, 13H), 1.24-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.4.
1H NMR (500 MHz, CD3OD) δ 4.52-4.44 (m, 0.5H), 4.44-4.37 (n, 0.5H), 3.66 (t, J=2.7 Hz, 1H), 3.58-3.52 (m, 0.5H), 3.51-3.26 (m, 3H), 3.02-2.90 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.49-2.39 (m, 2H), 2.34 (ddd, J=14.6, 10.8, 5.2 Hz, 0.5H), 2.22 (ddd, J=14.7, 10.5, 5.8 Hz, 0.5H), 2.11-1.69 (m, 11H), 1.64-1.25 (m, 13H), 1.25-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.701 (s, 1.5H), 0.697 (s, 1.5H); LCMS (ESI) m/z calcd for C31H52NO6S [M-Na]− 566.4, found 566.3.
1H NMR (500 MHz, CD3OD) δ 3.65 (t, J=2.7 Hz, 1H), 3.57 (dd, J=13.7, 6.0 Hz, 1H), 3.44 (dd, J=13.7, 6.8 Hz, 1H), 3.31-3.26 (m, 1H), 3.00-2.90 (m, 1H), 2.26 (ddd, J=13.9, 10.1, 5.1 Hz, 1H), 2.12 (ddd, J=13.9, 9.7, 6.7 Hz, 1H), 2.04-1.69 (m, 8H), 1.64-1.25 (m, 16H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.3.
1H NMR (400 MHz, DMSO-d6) δ 7.63-7.56 (m, 1H), 4.30 (d, J=4.6 Hz, 1H), 4.05 (d, J=5.0 Hz, 1H), 3.49 (s, 1H), 3.30-3.22 (m, 1H), 3.19-3.05 (m, 2H), 2.49-2.41 (m, 1H), 2.13-2.01 (m, 1H), 2.00-1.58 (m, 8H), 1.57-0.74 (m, 30H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.3.
1H NMR (500 MHz, CD3OD) δ4.34-4.25 (m, 1H), 3.76-3.67 (m, 2H), 3.65 (t, J=2.6 Hz, 1H), 3.36-3.25 (m, 1H), 3.14-2.99 (m, 2H), 2.33-2.22 (m, 1H), 2.17-2.06 (m, 1H), 2.04-1.70 (mi, 8H), 1.63-1.25 (m, 13H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.3.
1H NMR (500 MHz, CD3OD) δ4.34-4.26 (m, 1H), 3.76-3.67 (m, 2H), 3.65 (t, J=2.6 Hz, 1H), 3.36-3.26 (m, 1H), 3.14-2.99 (m, 2H), 2.32-2.24 (m, 1H), 2.16-2.07 (m, 1H), 2.03-1.68 (m, 8H), 1.65-1.25 (m, 13H), 1.24-1.05 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.3.
1H NMR (500 MHz, CD3OD) δ 4.34-4.28 (m, 1H), 3.65 (t, J=2.6 Hz, 1H), 3.35-3.25 (m, 1H), 2.91 (dt, J=10.2, 4.0 Hz, 1H), 2.32-2.11 (m, 3H), 2.07-1.69 (m, 11H), 1.64-1.25 (m, 17H), 1.24-1.05 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C32H54NO6S [M-Na]− 580.4, found 580.4.
1H NMR (500 MHz, CD3OD) δ 4.33-4.26 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.34-3.26 (m, 1H), 2.91 (dt, J=10.1, 4.1 Hz, 1H), 2.31 (ddd, J=14.2, 10.4, 5.2 Hz, 1H), 2.26-2.18 (m, 1H), 2.13 (ddd, J=14.2, 10.1, 6.3 Hz, 1H), 2.07-1.69 (m, 11H), 1.65-1.25 (m, 17H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C32H54NO6S [M-Na]− 580.4, found 580.4.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.35-3.26 (m, 1H), 3.05 (dd, J=13.9, 5.5 Hz, 1H), 2.88 (dd, J=13.9, 7.0 Hz, 1H), 2.22 (ddd, J=13.8, 10.3, 5.2 Hz, 1H), 2.07 (ddd, J=13.8, 10.0, 6.4 Hz, 1H), 2.03-1.69 (m, 8H), 1.63-1.24 (m, 16H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.3.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.35-3.27 (m, 1H), 3.05 (dd, J=13.9, 5.6 Hz, 1H), 2.88 (dd, J=13.9, 6.9 Hz, 1H), 2.23 (ddd, J=13.8, 10.1, 5.1 Hz, 1H), 2.07 (ddd, J=13.8, 9.8, 6.6 Hz, 1H), 2.03-1.70 (m, 8H), 1.63-1.25 (m, 16H), 1.24-1.05 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.87 (m, 6H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO6S [M-Na]− 540.3, found 540.3.
1H NMR (500 MHz, CD3OD) δ 4.39-4.30 (m, 1H), 3.65 (t, J=2.8 Hz, 1H), 3.35-3.26 (m, 1H), 3.03 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.3 Hz, 1H), 2.24 (ddd, J=13.8, 10.1, 5.2 Hz, 1H), 2.09 (ddd, J=13.8, 9.8, 6.7 Hz, 1H), 2.04-1.70 (m, 8H), 1.70-1.24 (m, 16H), 1.23-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.95-0.85 (m, 12H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C32H56NO6S [M-Na]− 582.4, found 582.4.
1H NMR (500 MHz, CD3OD) δ 4.42-4.33 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.35-3.26 (m, 1H), 3.01 (dd, J=14.0, 5.6 Hz, 1H), 2.90 (dd, J=14.0, 6.3 Hz, 1H), 2.22 (ddd, J=14.1, 9.3, 5.1 Hz, 1H), 2.11 (ddd, J=13.7, 9.0, 7.5 Hz, 1H), 2.04-1.70 (m, 8H), 1.70-1.24 (m, 16H), 1.23-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.95-0.86 (m, 12H), 0.69 (s, 3H); LCMS (ESI) m/z calcd for C32H56NO6S [M-Na]− 582.4, found 582.4.
1H NMR (400 MHz, DMSO-d6) δ 7.79 (s, 1H), 4.28 (d, J=4.7 Hz, 1H), 4.05 (d, J=5.0 Hz, 1H), 3.49 (s, 1H), 3.17-3.06 (m, 1H), 2.71-2.57 (m, 2H), 2.04-1.55 (m, 9H), 1.55-0.74 (m, 29H), 0.62-0.50 (m, 5H); LCMS (ESI) m/z calcd for C30H50NO6S [M-Na]− 552.3, found 552.3.
1H NMR (500 MHz, CD3OD) δ 3.87-3.40 (m, 6H), 3.35-3.24 (m, 1H), 2.47-2.17 (m, 4H), 2.06-1.69 (m, 8H), 1.64-1.25 (m, 13H), 1.24-1.06 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.71 (s, 1.5H), 0.70 (s, 1.5H); LCMS (ESI) m/z calcd for C30H50NO6S [M-Na]− 552.3, found 552.3.
1H NMR (500 MHz, CD3OD) δ 3.87-3.40 (m, 6H), 3.36-3.26 (m, 1H), 2.47-2.17 (m, 4H), 2.04-1.69 (m, 8H), 1.64-1.25 (m, 13H), 1.25-1.06 (m, 3H), 1.05-0.94 (m, 4H), 0.94-0.87 (m, 6H), 0.71 (s, 1.5H), 0.70 (s, 1.5H); LCMS (ESI) m/z calcd for C30H50NO6S [M-Na]− 552.3, found 552.3.
1H NMR (500 MHz, CD3OD) δ 3.81-3.75 (m, 1H), 3.73-3.68 (m, 1H), 3.65 (t, J=2.7 Hz, 1H), 3.59-3.44 (m, 2H), 3.35-3.27 (m, 1H), 3.11-3.02 (m, 2H), 2.58-2.32 (m, 4H), 2.31 (s, 3H), 2.29 (s, 3H), 2.06-1.68 (m, 8H), 1.65-1.25 (m, 13H), 1.25-1.06 (m, 3H), 1.05-0.95 (m, 4H), 0.94-0.86 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C32H57N2O6S [M-Na]− 597.4, found 597.4.
1H NMR, (500 MHz, CD3OD) δ 85:2-8.41 (m, 2H), 7.81-7.76 (m, 0.6H), 7.76-7.71 (m, 0.4H), 7.51-7.45 (m, 0.4H), 7.43-7.37 (m, 0.6H), 4.84-4.81 (m, 1H), 4.72-7.62 (m, 1H), 3.85-3.70 (m, 2H), 3.68-3.62 (m, 1H), 3.36-3.26 (m, 1H), 3.12-3.03 (m, 2H), 2.64-2.54 (m, 0.6H), 2.51-2.37 (m, 1H), 2.35-2.25 (m, 0.4H), 2.04-1.67 (m, 8H), 1.64-1.05 (m, 16H), 1.05-0.95 (m, 3H), 0.94-0.85 (m, 7H), 0.69 (s, 1.8H), 0.66 (s, 1.2H); LCMS (ESI) m/z calcd for C34H53N2O6S [M-Na]− 617.4, found 617.4.
1H NMR (500 MHz, CD3OD) δ7.53-7.46 (m, 2H), 7.46-7.38 (m, 1H), 7.35-7.29 (m, 2H), 4.13-4.06 (m, 2H), 3.63 (s, 1H), 3.34-3.25 (m, 1H), 3.09-3.02 (m, 2H), 2.17-2.08 (m, 1H), 2.02-1.93 (m, 1H), 1.93-1.64 (m, 8H), 1.62-1.15 (m, 13H), 1.14-0.85 (m, 10H), 0.70 (d, J=5.9 Hz, 3H), 0.62 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO6S [M-Na]− 602.4, found 602.4.
1H NMR (400 MHz, DMSO-d6) δ 7.83 (t, J=5.5 Hz, 1H), 4.29 (s, 1H), 4.08 (s, 1H), 3.93 (s, 1H), 3.77 (s, 1H), 3.48 (s, 1H), 3.23-3.16 (m, 2H), 3.15-3.08 (m, 1H), 2.32 (t, J=6.9 Hz, 2H), 2.14-1.55 (m, 10H), 1.55-1.05 (m, 13H), 1.01-0.70 (m, 11H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO6 [M-Na]− 506.3, found 506.3.
1H NMR (500 MHz, CD3OD) δ3.98-3.93 (m, 1H), 3.86-3.70 (m, 2H), 3.66 (t, J=2.7 Hz, 1H), 3.35-3.26 (m, 1H), 3.13 (s, 1.5H), 3.08-3.00 (m, 2H), 2.93 (s, 1.5H), 2.53 (ddd, J=15.4, 10.8, 5.1 Hz, 0.5H), 2.48-2.33 (m, 1H), 2.33-2.15 (m, 1.5H), 2.02 (td, J=12.1, 7.4 Hz, 1H), 1.97-1.68 (m, 7H), 1.64-1.25 (m, 12H), 1.18-1.08 (m, 1H), 1.08-0.93 (m, 4H), 0.93-0.87 (m, 6H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.3.
1H NMR (400 MHz, DMSO-d6) δ7.42-7.14 (m, 5H), 4.59 (s, 0.6H), 4.56-4.43 (m, 1.4H), 4.29 (d, J=4.4 Hz, 1H), 4.13 (d, J=3.4 Hz, 0.7H), 4.06 (d, J=3.1 Hz, 0.3H), 3.97-3.90 (m, 1H), 3.81 (s, 0.7H), 3.74 (s, 0.3H), 3.54-3.39 (m, 3H), 3.17-3.06 (m, 1H), 2.66-2.54 (m, 2H), 2.46-1.91 (m, 4H), 1.89-1.58 (m, 6H), 1.54-1.04 (m, 13H), 1.02-0.74 (m, 11H), 0.60 (s, 2.1H), 0.56 (s, 0.9H); LCMS (ESI) m/z calcd for C35H54NO7S [M-Na]− 632.4, found 632.3.
1H NMR (500 MHz, CD3OD) δ 3.98-3.94 (m, 1H), 3.90-3.79 (m, 1H), 3.77-3.64 (m, 4H), 3.59-3.53 (m, 1H), 3.52-3.43 (m, 1H), 3.35-3.26 (m, 1H), 3.13-3.04 (m, 2H), 2.58-2.45 (m, 1H), 2.43-2.30 (m, 1H), 2.24-2.15 (m, 1H), 2.05-1.68 (m, 8H), 1.65-1.26 (m, 12H), 1.20-0.94 (m, 5H), 0.94-0.86 (m, 6H), 0.76-0.67 (m, 3H); LCMS (ESI) m/z calcd for C30H52NO8S [M-Na]− 586.3, found 586.4.
1H NMR (500 MHz, CD3OD) δ4.66-4.56 (m, 0.4H) and 4.25-4.13 (m, 0.6H), 3.98-3.93 (m, 1H), 3.72-3.58 (m, 3H), 3.36-3.26 (m, 1H), 3.09-3.02 (m, 2H), 2.51-2.41 (m, 1H), 2.38-2.27 (m, 1H), 2.25-2.15 (m, 1H), 2.08-1.97 (m, 1H), 1.96-1.68 (m, 7H), 1.65-1.23 (m, 16H), 1.20-1.08 (m, 3H), 1.08-0.95 (m, 4H), 0.94-0.86 (m, 6H), 0.723 (s, 1.8H), 0.720 (s, 1.2H); LCMS (ESI) m/z calcd for C31H54NO7S [M-Na]− 584.4, found 584.4.
1H NMR (500 MHz, CD3OD) δ4.44 (tt, J=12.1, 3.9 Hz, 0.5H), 4.06-3.91 (m, 3.5H), 3.78-3.69 (m, 1H), 3.69-3.62 (m, 2H), 3.53-3.41 (m, 2H), 3.37-3.24 (m, 1H), 3.09-3.00 (m, 2H), 2.55-2.44 (m, 1H), 2.41-2.31 (m, 1H), 2.25-2.15 (m, 1H), 2.08-1.64 (m, 11H), 1.64-1.25 (m, 13H), 1.17-0.95 (m, 5H), 0.94-0.87 (m, 6H), 0.72 (s, 1.5H), 0.71 (s, 1.5H); LCMS (ESI) m/z calcd for C33H56NO8S [M-Na]− 626.4, found 626.4.
1H NMR (400 MHz, DMSO-d6) δ4.72 (d, J=12.5 Hz, 0.5H), 4.34-4.23 (m, 1.5H), 4.15-4.07 (m, 1H), 4.03 (d, J=13.4 Hz, 0.5H), 3.93 (t, J=4.9 Hz, 1H), 3.83-3.72 (m, 1.5H), 3.48 (s, 1H), 3.18-3.07 (m, 1H), 3.00-2.89 (m, 0.5H), 2.87-2.75 (m, 0.5H), 2.42-1.92 (m, 7H), 1.90-1.08 (m, 22H), 1.02-0.73 (m, 11H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO7S [M-Na]− 582.3, found 582.3.
1H NMR (500 MHz, CD3OD) δ 5.02 (d, J=9.7 Hz, 0.5H), 4.45 (d, J=12.9 Hz, 0.5H), 4.34-4.28 (m, 0.5H), 3.98-3.90 (m, 1.5H), 3.66 (t, J=2.7 Hz, 1H), 3.35-3.27 (m, 1H), 3.23 (dd, J=13.5, 11.2 Hz, 0.5H), 3.01 (td, J=13.2, 2.8 Hz, 0.5H), 2.79 (tt, J=11.3, 3.8 Hz, 0.5H), 2.75-2.65 (m, 1H), 2.59 (td, J=12.6, 2.7 Hz, 0.5H), 2.54-2.26 (m, 3H), 2.20 (td, J=12.1, 5.2 Hz, 1H), 2.02 (td, J=11.9, 7.2 Hz, 1H), 1.97-1.67 (m, 9H), 1.64-1.26 (m, 13H), 1.18-1.09 (i, 1H), 1.09-0.95 (m, 4H), 0.95-0.87 (m, 6H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO7S [M-Na]− 582.3, found 582.4.
1H NMR (400 MHz, DMSO-d6) δ 4.37 (d, J=13.0 Hz, 1H), 4.29 (d, J=4.3 Hz, 1H), 4.10 (d, J=3.4 Hz, 1H), 3.96-3.90 (m, 1H), 3.85 (d, J=13.5 Hz, 1H), 3.79 (s, 1H), 3.48 (s, 1H), 3.18-3.06 (m, 1H), 2.99-2.87 (m, 1H), 2.48-2.37 (m, 2H), 2.36-2.04 (m, 3H), 2.04-1.55 (m, 9H), 1.54-1.07 (m, 15H), 1.04-0.75 (m, 11H), 0.59 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO7S [M-Na]− 582.3, found 582.3.
1H NMR (400 MHz, DMSO-d6) δ 4.30 (d, J=4.3 Hz, 1H), 4.21-4.09 (m, 2H), 4.05-3.97 (m, 1H), 3.94 (d, J=4.9 Hz, 1H), 3.85 (t, J=9.0 Hz, 1H), 3.81-3.71 (m, 2H), 3.48 (s, 1H), 3.45-3.38 (m, 1H), 3.17-3.06 (m, 1H), 2.15-1.06 (m, 23H), 1.00-0.74 (m, 11H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C29H48NO7S [M-Na]− 554.3, found 554.3.
1H NMR (500 MHz, CD3OD) δ 3.97-3.93 (m, 1H), 3.66 (t, J=2.7 Hz, 1H), 3.35-3.27 (m, 1H), 3.20-3.12 (m, 2H), 2.26-2.15 (m, 2H), 2.10-1.96 (m, 2H), 1.96-1.70 (m, 7H), 1.64-1.24 (m, 18H), 1.12 (qd, J=12.0, 5.9 Hz, 1H), 1.05-0.95 (m, 4H), 0.91 (d, J=6.7 Hz, 6H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H2NO7S [M-Na]− 570.3, found 570.3.
1H NMR (500 MHz, CD3OD) δ 7.29-7.22 (m, 4H), 7.21-7.14 (m, 1H), 4.53-4.44 (m, 1H), 3.96-3.91 (m, 1H), 3.66 (t, J=2.8 Hz, 1H), 3.36-3.26 (m, 1H), 3.16 (dd, J=13.7, 6.0 Hz, 1H), 3.04-2.95 (m, 2H), 2.88 (dd, J=13.7, 8.1 Hz, 1H), 2.24-2.13 (m, 2H), 2.07-1.96 (m, 2H), 1.96-1.63 (m, 7H), 1.63-1.18 (m, 12H), 1.17-1.05 (m, 1H), 1.05-0.95 (m, 4H), 0.95-0.86 (m, 6H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C35H54NO7S [M-Na]− 632.4, found 632.4.
1H NMR (400 MHz, DMSO-d6) δ 7.70 (d, J=7.5 Hz, 1H), 7.29-7.11 (m, 5H), 4.29 (d, J=4.3 Hz, 1H), 4.17-4.06 (m, 2H), 3.93 (d, J=4.9 Hz, 1H), 3.78 (s, 1H), 3.49 (s, 1H), 3.17-3.07 (m, 2H), 2.75 (dd, J=13.3, 6.9 Hz, 1H), 2.53-2.51 (m, 2H), 2.15-1.05 (m, 23H), 1.00-0.75 (m, 11H), 0.57 (s, 3H); LCMS (ESI) m/z calcd for C35H54NO7S [M-Na]− 632.4, found 632.4.
1H NMR (500 MHz, CD3OD) δ 4.24-4.17 (m, 1H), 3.98-3.93 (m, 1H), 3.66 (t, J=2.7 Hz, 1H), 3.34-3.27 (m, 1H), 2.98-2.92 (m, 2H), 2.30 (ddd, J=13.7, 10.5, 5.1 Hz, 1H), 2.24-1.97 (m, 4H), 1.97-1.70 (m, 7H), 1.64-1.26 (m, 12H), 1.12 (qd, J=12.0, 5.8 Hz, 1H), 1.06-0.95 (m, 4H), 0.95-0.87 (m, 12H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C31H54NO7S [M-Na]− 584.4, found 584.4.
1H NMR (500 MHz, CD3OD) 4.27-4.20 (m, 1H), 3.98-3.93 (m, 1H), 3.66 (t, J=2.8 Hz, 1H), 3.35-3.27 (m, 1H), 2.97-2.91 (m, 2H), 2.27 (ddd, J=14.2, 9.6, 4.9 Hz, 1H), 2.23-2.11 (m, 2H), 2.08-1.96 (m, 2H), 1.96-1.69 (m, 7H), 1.65-1.24 (m, 12H), 1.17-1.06 (m, 1H), 1.06-0.96 (m, 4H), 0.95-0.85 (m, 12H), 0.70 (s, 3H); LCMS (ESI) m/z calcd for C31H54NO7S [M-Na]− 584.4, found 584.3.
1H NMR (500 MHz, CD3OD) δ 7.37-7.27 (m, 4H), 7.24-7.18 (m, 1H), 5.34 (dd, J=9.9, 3.8 Hz, 1H), 3.98-3.92 (m, 1H), 3.66 (d, J=2.8 Hz, 1H), 3.34-3.29 (m, 1H), 3.29-3.23 (m, 1H), 3.10 (dd, J=14.3, 3.8 Hz, 1H), 2.32 (ddd, J=13.8, 10.1, 5.0 Hz, 1H), 2.23-2.12 (m, 2H), 2.05-1.95 (m, 1H), 1.95-1.68 (m, 7H), 1.63-1.20 (m, 12H), 1.15-1.05 (m, 1H), 1.05-0.96 (m, 4H), 0.94-0.85 (m, 6H), 0.68 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO7S [M-Na]− 618.3, found 618.3.
1H NMR (400 MHz, DMSO-d6) δ 8.16 (d, J=6.3 Hz, 1H), 7.28-7.19 (m, 4H), 7.18-7.10 (m, 1H), 5.03-4.94 (m, 1H), 4.30 (d, J=4.3 Hz, 1H), 4.11 (d, J=3.5 Hz, 1H), 3.93 (d, J=4.9 Hz, 1H), 3.79 (s, 1H), 3.48 (s, 1H), 3.17-3.06 (m, 1H), 2.85 (dd, J=13.9, 9.2 Hz, 1H), 2.67 (dd, J=13.8, 4.0 Hz, 1H), 2.15-1.91 (m, 4H), 1.90-1.56 (m, 6H), 1.54-1.03 (m, 13H), 0.99-0.75 (m, 11H), 0.56 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO7S [M-Na]− 618.3, found 618.3.
1H NMR (500 MHz, CD3OD) δ 4.52-4.45 (m, 0.5H), 4.45-4.38 (m, 0.5H), 3.99-3.93 (m, 1H), 3.66 (t, J=2.8 Hz, 1H), 3.59-3.53 (m, 0.5H), 3.51-3.26 (m, 3H), 3.02-2.92 (m, 1H), 2.74 (dd, J=13.3, 10.6 Hz, 0.5H), 2.50-2.39 (m, 2H), 2.35 (ddd, J=15.3, 10.6, 5.1 Hz, 0.5H), 2.28-2.15 (m, 1.5H), 2.11-1.70 (m, 11H), 1.64-1.27 (m, 12H), 1.18-0.95 (m, 5H), 0.95-0.86 (m, 6H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C31H52NO7S [M-Na]− 582.3, found 582.3.
1H NMR (500 MHz, CD3OD) δ 3.97-3.93 (m, 1H), 3.66 (t, J=2.7 Hz, 1H), 3.58 (dd, J=13.7, 5.8 Hz, 1H), 3.42 (dd, J=13.7, 7.2 Hz, 1H), 3.36-3.27 (m, 1H), 2.99-2.90 (m, 1H), 2.28 (ddd, J=13.8, 10.2, 5.0 Hz, 1H), 2.23-2.08 (m, 2H), 2.01 (td, J=12.1, 7.4 Hz, 1H), 1.96-1.69 (m, 7H), 1.64-1.47 (m, 6H), 1.47-1.24 (m, 9H), 1.12 (qd, J=12.1, 5.8 Hz, 1H), 1.05-0.94 (m, 4H), 0.94-0.86 (i, 6H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (500 MHz, CD3OD) δ 4.34-4.26 (m, 1H), 3.95 (t, J=3.0 Hz, 1H), 3.76-3.64 (m, 3H), 3.35-3.27 (m, 1H), 3.14-3.07 (m, 1H), 3.06-2.99 (m, 1H), 2.34-2.24 (m, 1H), 2.24-2.08 (m, 2H), 2.06-1.96 (m, 1H), 1.96-1.70 (m, 7H), 1.64-1.47 (m, 6H), 1.47-1.27 (m, 6H), 1.18-1.07 (m, 1H), 1.06-0.95 (m, 4H), 0.94-0.86 (m, 6H), 0.72 (d, J=1.1 Hz, 3H); LCMS (ESI) m/z calcd for C29H50NO8S [M-Na]− 572.3, found 572.2.
1H NMR (500 MHz, CD3OD) δ 4.33-4.27 (m, 1H), 3.99-3.93 (m, 1H), 3.69-3.64 (m, 1H), 3.34-3.27 (m, 1H), 2.91 (dt, J=10.1, 4.1 Hz, 1H), 2.33 (ddd, J=14.2, 10.2, 5.1 Hz, 1H), 2.27-2.09 (m, 3H), 2.06-1.70 (m, 11H), 1.64-1.27 (m, 16H), 1.18-1.06 (m, 1H), 1.06-0.94 (m, 4H), 0.94-0.86 (m, 6H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C32H54NO7S [M-Na]− 596.4, found 596.3.
1H NMR (400 MHz, DMSO-d6) δ 7.68 (d, J=7.5 Hz, 1H), 4.30 (d, J=4.2 Hz, 1H), 4.10 (d, J=3.4 Hz, 1H), 4.04-3.91 (m, 2H), 3.78 (s, 1H), 3.48 (s, 1H), 3.18-3.06 (m, 1H), 2.60 (dd, J=13.4, 4.6 Hz, 1H), 2.45 (dd, J=13.4, 8.0 Hz, 1H), 2.14-1.06 (m, 26H), 1.02-0.74 (m, 11H), 0.58 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (500 MHz, CD3OD) δ 4.37-4.27 (m, 1H), 3.97-3.93 (m, 1H), 3.66 (t, J=2.8 Hz, 1H), 3.34-3.27 (m, 1H), 3.05 (dd, J=13.9, 5.5 Hz, 1H), 2.88 (dd, J=13.9, 7.0 Hz, 1H), 2.29-2.15 (m, 2H), 2.13-1.97 (m, 2H), 1.97-1.69 (m, 7H), 1.64-1.47 (m, 6H), 1.47-1.26 (m, 9H), 1.12 (qd, J=11.9, 5.7 Hz, 1H), 1.05-0.94 (m, 4H), 0.93-0.87 (m, 6H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C29H50NO7S [M-Na]− 556.3, found 556.2.
1H NMR (500 MHz, CD3OD) δ 4.39-4.30 (m, 1H), 3.99-3.92 (m, 1H), 3.66 (t, J=2.6 Hz, 1H), 3.35-3.26 (m, 1H), 3.03 (dd, J=14.0, 5.5 Hz, 1H), 2.90 (dd, J=14.0, 6.4 Hz, 1H), 2.30-2.15 (m, 2H), 2.15-2.06 (m, 1H), 2.06-1.97 (m, 1H), 1.97-1.25 (m, 22H), 1.18-1.06 (m, 1H), 1.05-0.85 (m, 16H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C32H56NO7S [M-Na]− 598.4, found 598.4.
1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J=8.6 Hz, 1H), 4.30 (d, J=4.3 Hz, 1H), 4.13-4.02 (m, 2H), 3.94 (d, J=4.9 Hz, 1H), 3.78 (s, 1H), 3.48 (s, 1H), 3.17-3.06 (m, 1H), 2.59 (dd, J=13.5, 4.5 Hz, 1H), 2.49-2.41 (m, 1H), 2.14-1.86 (m, 4H), 1.87-1.05 (m, 22H), 1.03-0.72 (m, 17H), 0.57 (s, 3H); LCMS (ESI) m/z calcd for C32H56NO7S [M-Na]− 598.4, found 598.4.
1H NMR (500 MHz, CD3OD) δ 3.96-3.92 (m, 1H), 3.66 (t, J=2.7 Hz, 1H), 3.34-3.25 (m, 1H), 3.03 (s, 2H), 2.27-2.14 (m, 2H), 2.11-1.96 (m, 2H), 1.96-1.70 (m, 7H), 1.64-1.24 (m, 12H), 1.11 (qd, J=12.0, 5.8 Hz, 1H), 1.05-0.86 (m, 12H), 0.81-0.76 (m, 2H), 0.71 (s, 3H); LCMS (ESI) m/z calcd for C30H50NO7S [M-Na]− 568.3, found 568.3.
1H NMR (500 MHz, CD3OD) δ 4.00-3.91 (m, 1H), 3.89-3.40 (m, 6H), 3.36-3.25 (m, 1H), 2.47-2.15 (m, 5H), 2.07-1.97 (m, 1H), 1.97-1.70 (m, 7H), 1.64-1.27 (m, 12H), 1.13 (qd, J=11.9, 5.3 Hz, 1H), 1.07-0.94 (m, 4H), 0.94-0.86 (m, 6H), 0.73 (s, 1.5H), 0.72 (s, 1.5H); LCMS (ESI) m/z calcd for C30H50N7S [M-Na]− 568.3, found 568.3.
1H NMR (500 MHz, CD3OD) δ 3.95 (d, J=2.3 Hz, 1H), 3.88-3.40 (m, 6H), 3.34-3.26 (m, 1H), 2.47-2.15 (m, 5H), 2.08-1.97 (m, 1H), 1.97-1.70 (m, 7H), 1.64-1.26 (m, 12H), 1.13 (qd, J=11.7, 5.2 Hz, 1H), 1.07-0.93 (m, 4H), 0.93-0.86 (m, 6H), 0.73 (s, 1.5H), 0.72 (s, 1.5H); LCMS (ESI) m/z calcd for C30H50NO7S [M-Na]− 568.3, found 568.3.
1H NMR (500 MHz, CD3OD) δ 3.98-3.93 (m, 1H), 3.81-3.75 (m, 1H), 3.73-3.68 (m, 1H), 3.66 (t, J=2.8 Hz, 1H), 3.59-3.45 (m, 2H), 3.35-3.27 (m, 1H), 3.11-3.02 (nm, 2H), 2.58-2.32 (m, 4H), 2.31 (s, 3H), 2.28 (s, 3H), 2.20 (td, J=12.3, 5.2 Hz, 1H), 2.02 (td, J=12.1, 7.4 Hz, 1H), 1.97-1.70 (m, 7H), 1.64-1.27 (m, 12H), 1.18-0.96 (m, 5H), 0.94-0.87 (m, 6H), 0.72 (s, 3H); LCMS (ESI) m/z calcd for C32H57N2O7S [M-Na]− 613.4, found 613.4.
1H NMR (400 MHz, DMSO-d6) δ8.51-8.40 (m, 2H), 7.62-7.55 (m, 1H), 7.43-7.38 (m, 0.4H), 7.36-7.31 (m, 0.6H), 4.66 (s, 0.4H), 4.59-4.46 (m, 1.6H), 4.29 (d, J=4.3 Hz, 1H), 4.15-4.05 (m, 1H), 3.97-3.91 (m, 1H), 3.83-3.72 (m, 1H), 3.56-3.38 (m, 3H), 3.18-3.06 (m, 1H), 2.68-2.54 (m, 2H), 2.46-2.37 (m, 1H), 2.37-2.24 (m, 1H), 2.14-1.91 (m, 2H), 1.90-1.57 (m, 6H), 1.56-1.08 (m, 13H), 1.03-0.74 (m, 11H), 0.59 (s, 1.8H), 0.56 (s, 1.2H); LCMS (ESI) m/z calcd for C34H53N2O7S [M-Na]− 633.4, found 633.4.
1H NMR (500 MHz, CD3OD) δ7.52-7.46 (m, 2H), 7.45-7.38 (m, 1H), 7.35-7.29 (m, 2H), 4.13-4.06 (m, 2H), 3.85 (s, 1H), 3.64 (s, 1H), 3.34-3.25 (m, 1H), 3.09-3.03 (m, 2H), 2.20-2.10 (m, 2H), 2.04-1.65 (m, 9H), 1.60-1.34 (m, 8H), 1.33-1.14 (m, 4H), 1.13-0.84 (m, 8H), 0.77 (d, J=6.1 Hz, 3H), 0.64 (s, 3H); LCMS (ESI) m/z calcd for C34H52NO7S [M-Na]− 618.3, found 618.4.
To evaluate anti-inflammatory efficacy, an inflammatory response was induced in J774A.1 (Mouse BALB/c monocyte macrophage cell line) cells derived from mouse macrophages by LPS (lipopolysaccharide) and LPS+ATP (adenosine triphosphate), and the efficacy of taurine-bile acid derivatives to inhibit the production of inflammatory cytokines (IL-1β, TNF-α) was measured. After treating J774A.1 cells with 1 μM of a taurine-bile acid derivative, the degree to which the secretion of TNF-α among cytokines was suppressed was measured in the experimental group in which an inflammatory response was induced by LPS, and the extent to which IL-1β secretion among cytokines was suppressed was measured in the experimental group in which an inflammatory response was induced with LPS+ATP. The ability of taurine-bile acid derivatives to inhibit cytokine production was graded compared to taurodeoxycholic acid, a positive control. The grading criteria are A: over 100%, B: over 50% and under 100%, C: between 20% and under 50%, and D: under 20%. The measurement results are as shown in Table 1 below.
To evaluate anti-inflammatory efficacy, U937 cells (human monocytic cell line) were differentiated into macrophages using PMA (phorbol 12-myristate 13-acetate) and then induced an inflammatory response with Pam2CSK4 (Pam2CysSerLys4) or BzATP (2′(3′)—O-(4-Benzoylbenzoyl)adenosine 5′-triphosphate), the efficacy of taurine-bile acid derivatives in suppressing inflammatory cytokine (IL-1β, TNF-α) production was measured.
Using PMA, U937 cells were differentiated into macrophages, and the extent of TNF-α secretion inhibition was measured in an experimental group where taurine-bile acid derivatives was treated, followed by induction of inflammatory response with Pam2CSK4, and in the experimental group in which an inflammatory response was induced with BzATP, the extent to which IL-1β secretion among cytokines was suppressed was measured.
The ability of taurine-bile acid derivatives to inhibit cytokine production was expressed in terms of IC50 (μM) values. The standards for TNF α inhibition ability are A: less than 0.5, B: 0.5 to less than 1.0, C: 1.0 to less than 2.0, D: 2.0 or more, and the IL-1β inhibition ability grade standards are A: less than 0.05, B: 0.05 to less than 0.10, C: 0.10 or more and less than 0.20, D: 0.20 or more. The measurement results are as shown in Table 2 below.
A new compound containing the taurine derivative of the present invention can be prepared, and it can be developed into a useful therapeutic agent, so it can be used in the pharmaceutical industry.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2021-0098148 | Jul 2021 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2022/010998 | 7/26/2022 | WO |
